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The risk factors for infection were evaluated retrospectively 
in 107 neutropenic patients without underlying malignancy or cyto¬ 
toxic drug therapy. Neutrophil count was an independent risk factor 
for infection, with the incidence of infection increasing as the 
neutrophil count decreased. The critical neutrophil count, below 
which the incidence of infection was significantly increased was 
250/mnr*, (p<.001). Eighty five percent of the <250 group entered with, 
or developed infection. Additional risk factors for infection included 
increased duration of neutropenia, age less than 1 year old, male sex, 
hypogammaglobulinemia, and recent antibiotic therapy. Fever was pre¬ 
dictive of infection in 85% of cases. 
The major consequence of infection was mortality, and the group 
O 
with PMN’s 1250/mm had three times the mortality of all other subjects 
(10% vs. 3% respectively). Thus neutropenic patients with no other 
evidence of host impairment appear to be at greatest risk of infection 
when the neutrophil count drops below 250. 
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The role of the neutrophil in host defense, and the association 
between neutropenia and infection have been well documented (10,20) . 
However, the bulk of the published studies have involved leukemic pa¬ 
tients in whom neutropenia was only one manifestation of their general¬ 
ized host impairment. In addition to cellular immaturity, the other 
factors that contributed to their increased risk for infection included 
malignancy and cytotoxic therapy (40,9). Most studies, including the 
classic study by Bodey (10), examined such groups of leukemic patients 
and discovered a definite predisposition to infection when tha neutrophil 
count falls below 1000. 
There are no published studies which directly relate the risk of 
infection in the neutropenic patient in whom there is no other obvious 
evidence of host impairment. This group of patients usually carries 
the diagnoses of idiopathic aplastic anemia or idiopathic neutropenia. 
With current studies suggesting the effectiveness of prophylactic moda¬ 
lities in preventing infections in the severely immuno-compromised host 
such as barrier reverse isolation and oral non-absorbable antibiotics 
(77,78), it has become increasingly important to recognize the 
critical granulocyte level at which the risk of infection is 
significantly increased. Furthermore, with the emergence of bone 
marrow transplantation as a therapeutic modality in some patients with 




may provide some guiding principles to appropriately prepare these 
patients for transplantation before infection has developed (95,94). 
With these considerations in mind, we have undertaken this 
retrospective clinical study to investigate the risk of infection in 
the neutropenic patient who does not harbor a hematologic malignancy 
and who is not receiving cytotoxic drug therapy. 
The questions we attempted to answer in this study include: 
1. How many neutropenic patients are seen at a University 
Hospital over a 10 year period, and what are the character¬ 
istics of this group? 
2. What is the incidence of infection? 
3. At what level of neutropenia is the risk of infection 
increased? 
4. When do such infections occur? 
5. What are the risk factors for infection? 
6. What are the consequences of infection? 
7. What is the survival of these patients in the hospital? 
8. What are the risk factors for mortality? 

THE NORMAL GRANULOCYTE LIFE CYCLE 
In order to more fully appreciate the causes and consequences 
of neutropenia, a brief discussion of the life cycle of the granulocyte 
would be instructive. The term granulocyte is often loosely used to 
refer to neutrophils, but strictly speaking refers to eosinophils and 
basophils as well. 
Granulocytes are normally produced in the bone marrow where they 
arise from precursor cells by a process of proliferation and maturation. 
The precursor cell in the bone marrow from which all the blood cells 
are believed to arise, is the pluripotent stem cell (32) . A stem cell 
is a cell with two capabilities: the ability to replicate itself, and 
the ability to form more differentiated daughter cells. A pluripotent 
stem cell is one with the capacity to differentiate into more than one 
cell line, i.e., the erythrocyte, granulocyte, megakaryocyte, and mono¬ 
cyte series. In contrast, a unipotent stem cell can replicate itself, 
but can only differentiate along one pathway. For example, the myelo¬ 
blast is a unipotent stem cell "committed" to the granulocyte pathway 
(commitment to neutrophilic, eosinophilic, or basophilic development 
occurs later at the promyelocyte stage of cell development). Many 
investigators believe that cells of the mononuclear-phagocyte series 
(monocytes and macrophages) share a common committed stem cell with the 




The influences that determine the direction of differentiation of 
the granulocyte stem cells are not entirely clear. Relatively little 
is knoxtfn about the mechanisms which regulate cellular differentiation 
from pluripotent to committed stem cells, however several factors are 
believed to be important. Pluripotent stem cells may "sense" the 
utilization of committed granulocytic stem cells, thereby signaling further 
differentiation in this direction. The stromal environment of the bone 
marrow or spleen may exert regulating influences on stem cells. These 
stromal elements have been referred to collectively as the hematopoietic 
inductive microenvironment. 
In addition to the short range environmental influences mentioned 
above, many long range hormonal influences have been described. These 
stimulators of granulopoiesis have been called leukopoietins. The best 
documented leukopoietin is referred to as Colony Stimulating Activity 
(CSA). CSA is a 45,000 dalton glycoprotein derived from human urine, 
thought to stimulate granulopoiesis in a manner analogous to the effect 
of erythropoietin on red blood cell production. Serum and urine CSA 
preparations increase granulocyte production when injected into mice. 
Peripheral blood leukocytes form a potent source of human CSA, and the 
blood cell primarily responsible for its elaboration is the monocyte. The 
existence of the monocyte as the principal source of CSA is consistent with 
the evidence linking monocytes and granulocytes to a common committed 
stem cell. (See Figure 2) 
Under the microenvironmental and hormonal influences mentioned above, 
the pluripotent stem cell develops into a committed stem cell, the myeloblast. 
\ 
5 
The myeloblast, with its active Golgi apparatus and endoplasmic reticulum 
develops into the promyelocyte with its primary (or azurophilic) granules. 
These granules contain myeloperoxidase, acid hydrolases, neutral pro¬ 
teases, cationic antibacterial proteins, and some of the cells' lysozyme. 
The myelocyte, the next stage of development, contains secondary (or 
specific) granules which contain lactoferrin, aminopeptidase, B-^ 
binding protein, and most of the cellular lysozyme. The myelocyte has 
fewer mitochondria but has begun to acquire the unique oxygen metabolism 
that characterizes the mature polymorphonuclear leukocyte (PMN). Beyond 
the myelocyte stage, neutrophilic cells do not divide; instead their 
nuclear chromatin becomes condensed, the cell diminishes in size, and 
cytoplasmic glycogen accumulates. Approximately 8 to 14 days are 
required for a cell to move through the 4 to 6 cell divisions and complete 
maturation, from the myeloblast to a mature PMN. (See Figure 3) 
Q 
The normal human neutrophil production rate is approximately 1.6x10 
cells per kilogram per day (22). These cells remain within the marrow until 
their differentiation and maturation is completed. In contrast, mono¬ 
cytes are released into the circulation as immature cells, some of 
which can divide again after passing through the blood. 
There are two large pools of granulocytes in the bone marrow, the 
mitotic or proliferative compartment, and the maturation-storage compart¬ 
ment (32). Myeloblasts, promyelocytes, and myelocytes are capable of 
replication, thus they constitute the mitotic compartment. Metamyelocytes, 
bands, and mature PMN's are nonreplicating and constitute the maturation 
and storage compartment. Studies have shown that the progression from 
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metamyelocyte to mature PMN is very orderly within this compartment, 
and have suggested a "first in, first out" pattern for cells leaving 
this compartment and entering the peripheral circulation (16). With 
the completion of maturation, the mature PMN's are stored in the bone 
marrow, and are referred to as the mature granulocyte reserve. This 
reserve usually contains more PMN’s than are normally circulating in the 
blood. These mature neutrophils may be readily released by a number of 
stimuli, including stress, corticosteroids, and bacterial endotoxin. 
The final common pathway in release of neutrophils by the marrow is 
believed to be mediated by neutrophil releasing factor (29) . This 
factor can be isolated from the plasma, and is felt to play an important 
role in regulating acute changes in the numbers of circulating neutrophils 
by affecting their release from the bone marrow. The average time sequence 
given for the stages of development in bone marrow include a 3 to 4 day 
period of intramedullary proliferative buildup, followed by a 5 to 7 
day period of intramedullary maturation (17). 
Under normal circumstances, granulocytes leaving the marrow are 
fully functional cells capable of chemotaxis, phagocytosis, endocytosis, 
degranulation, and bacterial killing. Granulocytes leaving the marrow 
storage compartment enter the blood, without significant reentry into 
the marrow, where they are approximately equally divided between cells 
freely circulating (circulating granulocyte pool, CGP) and those that 
are transiently and reversibly adherent to vascular endothelium (marginated 
granulocyte pool, MGP). Together, all the neutrophils in the vascular 
space constitute the total blood granulocyte pool, TBGP. Shifts between 
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the MGP and CGP occur readily in response to a variety of factors 
affecting blood flow in capillary beds or altering membrane properties 
of granulocytes or endothelium. For example, exercise, epinephrine, 
or stress cause a shift of cells from the MGP to the CGP. 
After a variable period in the circulating or marginated pools, 
the cells migrate through the vascular endothelium into the tissues. 
Granulocytes do not reenter the circulation once they have entered the 
tissues; the flow of cells is unidirectional. The rate of disappearance 
of cells from the circulation has a half-time of about 6.5 hours. The 
exponential disappearance of cells from the blood suggests that they 
leave in a random manner (32). Thus granulocytes released from the 
marrow are as likely to leave the blood as are neutrophils that have been 
circulating for several hours. 
The total number of cells released from the marrow per unit time 
may be increased by one or more of the following mechanisms: 
1. Saturation time may be shortened. 
2. divisions may be skipped, and 
3. release into the blood may occur prematurely. 
Many abnormalities of granulocyte production, maturation, and 
distribution may be accompanied by release of immature granulocytes 
from the marrow. Immature granulocytes (normal or leukemic) show 
decreased motility, decreased chemotactic responsiveness, and decreased 
phagocytic and bactericidal functions. They also exhibit a longer 
lifespan in the circulation, and may reenter the blood and marrow from 
the tissues (17). This is in direct contrast with most abnormalities 
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of erythrocytes and platelets which, in general, shorten the lifespan 
of these cells. If the cells are very immature (myelocyte stage or 
earlier) they may divide again in the blood or tissues. Thus the basic 
principles of unidirectional kinetics characteristic of normal granu¬ 
locyte production does not hold for immature or incompletely differentiated 
granulocytes (17). 
The duration and precise activity of many neutrophils after they 
leave the circulation are poorly documented. The migration of granulocytes 
into areas of inflammation has been widely studied, but little is known 
of the fate of granulocytes in normal tissue. Granulocytes normally 
migrate into the lung, spleen, liver and oral cavity, and gastrointestinal 
tract. They may be lost from mucosal surfaces, die in the tissues or 
be sequestered by the reticuloendothelial system. Their average lifespan 
in the tissues is assumed to be several days (16). 
In inflammation, the egress of granulocytes from the vascular space 
is facilitated by changes in the vascular endothelial permeability, as 
well as the formation of chemotactic factors at inflammatory sites (17). 
These chemotactic factors can include C3a, C5a, and C567 components of the 
complement system, low molecular weight substances released by bacteria, 
kallikrein, plasminogen activator, and transfer factor to name several. 
The normally random motility of the cells will be directed to move along 
an increasing concentration gradient of these factors to enable them to 
reach tissue sites of inflammation or infection. At the inflammatory site, 
phagocytosis is facilitated by humoral substances, opsonins, which have 
coated the surface of the foreign material to be ingested. Immunoglobulins 
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and complement are the best characterized opsonins, with complement playing 
the major role in phagocytosis of many bacteria by the deposition of 
C3b on the bacterial surface (67). 
Phagocytosis stimulates numerous intracellular events including 
increased oxygen consumption, glycogenolysis, glucose oxidation via the 
hexose-monophosphate shunt, and the production of superoxide and hydrogen 
peroxide (43). Within the cell, phagocytized particles remain in a 
vacuole, and the contents of the secondary and then the primary granules 
are sequentially emptied into this vacuole. The vacuolar pH falls to 
about pH 6.0 favoring the activity of a variety of acid hydrolases (16) . 
The neutrophil possesses a variety of bactericidal mechanisms giving it 
an "overkill" capacity. The best characterized bactericidal mechanism 
involves myeloperoxidase combining with hydrogen peroxide and a halide 
such as iodide or chloride (43) . This system is also effective against 
viruses, fungi, and mycoplasma (16). The neutrophil usually degenerates 
after it digests the phagocytized material, and that, together with 





Granulocyte disorders can be classified into two main 
categories (43): 
1. Quantitative abnormalities. 
2. Qualitative abnormalities. 
Qualitative abnormalities of granulocytes usually implies a normal 
number of improperly functioning granulocytes. These abnormalities can 
include defects of mobility and chemotaxis, bactericidal activity, or 
phagocytosis. They may occur in association with anomalies of nucleus 
and cytoplasm. Certain disease states have been known to cause, or be 
associated with qualitative defects in granulocyte function, including 
"Lazy Leukocyte" Syndrome (54), Chediak-Higashi Syndrome (8), and 
Chronic Granulomatous Disease (92,21,5), chronic alcoholism (13), SLE (88), 
rheumatoid arthritis (55), Diabetes mellitus (58) and uremia (86) (See 
Table 33). 
Quantitative abnormalities of granulocytes refer to a reduced or 
increased number of normally functioning granulocytes, i.e., granulo¬ 
cytopenia or granulocytosis, respectively. Neutropenia refers specifically 
to an absolute reduction in peripheral neutrophils, and although technically 
imprecise, granulocytopenia has come to mean that as well. 
The absolute number of circulating neutrophils is calculated as 
the product of the total leukocyte count and the percent of neutrophils 
in the differential leukocyte count. In the Western hemisphere, the 

11 
lower limit of normal in healthy adults is an absolute neutrophil count 
of about 1500-1600 per mm^. There are some notable exceptions to this 
limit, and Yemenite Jews as well as Blacks in the U.S. and Africa often 
have a lower limit of normal. This is considered a benign variant (29) . 
In calculating the absolute neutrophil count, the assumption is 
made that the peripheral leukocyte counts are a reasonably accurate re¬ 
flection of the total leukocyte pool, including the CGP, MGP, and marrow 
storage pool. Rapid temporary shifts from one compartment to another 
may invalidate the peripheral count as a reliable index of the blood 
granulocyte pool. For example, blood is sampled from the CGP, however 
if there is a sudden shift of granulocytes from the CGP to the MGP just 
prior to sampling, the peripheral counts would be low despite having no 
change in the total circulating leukocyte pool. Accordingly, the calcu¬ 
lated absolute neutrophil count would be spuriously lower and therefore 
a poor indicator of the ability to generate an inflammatory response. 
This is one of many potential mechanisms by which cell counts may inaccu¬ 
rately reflect the total circulating neutrophils. Neutrophil counts 
may be spuriously low in electronic counters because of excessive leuko¬ 
cyte clumping (e.g., in the presence of certain paraproteins), because 
of a delay in counting, or excessive fragility of abnormal leukocytes (29) . 
Generally, neutropenia results either from diminished granulocyte 
production or from accelerated peripheral utilization, alone or in combi¬ 
nation with one another (29). More specifically these mechanisms include: 
A. Reduced delivery of mature granulocytes from the marrow to 
the peripheral blood pools (decreased effective granulopoiesis) 
as a consequence of: 
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1) decreased myeloid proliferation in the bone 
marrow (reduced granulopoiesis). 
2) increased production of abnormal or ineffective 
granulocytes (increased ineffective granulopoiesis) 
3) impaired release of granulocytes from the marrow 
storage compartment. 
B. Increased utilization or loss of peripheral blood granulocytes 
due to: 
1) accelerated diapedesis of mature granulocytes into 
tissues in response to: 
a) infection, or 
b) inflammation 
2) reduced survival due to: 
a) a maturation defect 
b) a leukotoxic factor (e.g., antineutrophil 
antibodies), 
c) increased reticuloendothelial system 
activity (i.e., hypersplenism) 
3) temporary or prolonged shifts into the marginal 
pool. 
These alterations in granulocyte kinetics may be acute, chronic, inter¬ 
mittent or cyclic. 
Finch has constructed a functional classification of neutropenias 
utilizing five major categories (29) (See Figure 4). 
■ 
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Type I or Reduced Granulopoiesis involves decreased myeloid prolife¬ 
ration: the number of granulocytes entering the peripheral blood (the 
effective granulopoiesis) from the marrow is inadequate to maintain a 
normal level, in the face of normal rates of egress from the peripheral 
circulation. In these situations marrow storage, marginal,and circulating 
granulocyte pools are reduced in size. Neutrophil mobilization at sites 
of inflammation is impaired. The total neutrophil turnover is reduced, 
but neutrophil survival is normal. 
Type II or Increased Ineffective Granulopoiesis involves increased 
myeloid proliferation but the number of mature granulocytes entering 
the peripheral blood is reduced. The inability of mature granulocytes 
to leave the marrow may be due to an increase in the intramedullary death 
of myeloid precursors or because of a lack of the necessary stimulus for 
marrow release. As in Type I neutropenia, the MGP, CGP, and bone marrow 
pool are reduced. In addition, there is some evidence that in many of 
these conditions neutrophil survival is also shortened. 
Type III or Reduced Granulocyte Survival involves the increased 
destruction or utilization of peripheral granulocytes. In this case, 
the increased peripheral utilization stimulates marrow granulopoiesis 
and an increased delivery of mature neutrophils to the blood (increased 
effective granulopoiesis). However, if the depletion rate exceeds the 
production rate, neutropenia develops. This condition may be due to 
leukotoxins, leukocyte antibodies, increased splenic sequestration, or 
increased leukophagocytosis by hyperfunctioning RES cells. Blood 
neutrophil survival is short, and the turnover rate is markedly increased. 
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When possible, removal of the factor responsible for the peripheral 
neutrophil destruction is usually followed by rapid resolution of the 
neutropenia with restoration of normal cell kinetics. However, in 
some cases, chronic peripheral destruction may eventually lead to bone 
marrow failure. 
Type IV or Combination Granulocytopenia involves a combination 
of Type I or II, with Type III. Reduction in effective granulopoiesis 
is combined with a shortened neutrophil survival. This is the most 
common mechanism producing neutropenia. 
Type V or Pseudoneutropenia is an apparent neutropenia due to 
reduction in the size of the CGP without change in the size of the total 
granulocyte pool. This usually results from a shift to the MGP. Leuko¬ 
cyte kinetics are normal. 
The five functional classes above describe the general mechanisms 
of neutropenia. The causes of neutropenia include malignancy, drug 
reactions, industrial solvent exposure, allergic reactions, leukotoxin 
production, hypersplenism secondary to a number of conditions, vitamin 
deficiencies, sepsis, cancer chemotherapy (e.g., alkylating agents, anti¬ 
metabolites, etc.), inflammation, and vasomotor changes, in addition 
to the idiopathic variety (29,35). The exact site or sites of granulocyte 
production and utilization that are affected by each of these etiologic 
agents in producing neutropenia are not fully characterized, and there 
is a great deal of conjecture on this. It is beyond the scope of this 
paper to deal with the various theories. Suffice it to say that most 
agents can affect various steps in granulocyte production or survival 
(See Figures 5 and 6). 
. 
NORMAL HOST DEFENSE 
Normal host defense against microbial invasion can be divided 
into four systems: 
1. Mucocutaneous barriers 
2. The inflammatory response 
3. The humoral immune system 
4. The cellular immune system. 
Modification of any one of these components may predispose the host 
to infection (35) . 
Mucocutaneous Barriers 
The skin and mucous membranes serve as an interface between man 
and the internal and external microbial environments to which he is 
exposed. Each environment is inhabited by its own "normal flora" 
that varies by geographic location and body site. Four important 
elements of the mucocutaneous barrier system are exposure to non-indigenous 
flora, mechanical barriers to invasion, interbacterial inhibition, and 
secretory immunoglobulin A (IgA). 
Invasion by microorganisms cannot occur without prior exposure. 
Schimpff et al., (79) in a study of leukemic patients, demonstrated that 
isolation of an offending organisms from serial surveillance cultures of 
various body sites preceded infection with that organism in 86% of cases. 
In almost half of these cases, the offending organism was not part of the 




Even prior exposure to an organism is usually insufficient for 
infection in the normal host, unless there is a breakdown of the me¬ 
chanical barriers of skin and/or mucous membranes (35). This allows 
resident flora to become pathogenic. 
Although the process by which normal flora can inhibit prolifera¬ 
tion of one another or non-indigenous organisms on mucocutaneous surfaces 
is well documented, the mechanism is unknown (28). 
Secretory IgA is known to be protective against viral infections 
that require mucosal penetration, and is believed to be involved in 
regulating bacterial invasion (68,97). 
Inflammatory Response 
The inflammatory response involves the delivery and normal function 
of inflammatory cells. These functions include generation of chemotactic 
factors, intact vascular supply capable of inflammatory cell transport, 
adequate numbers of normally functioning phagocytes (as described in 
the previous chapter, WBC Life Cycle), and opsonins. Various defects in 
the above mechanisms have been characterized and categorized into disease 
entities (e.g., Chediak-Higashi Syndrome, Lazy Leukocyte Syndrome, and 
Chronic Granulomatous Disease) all of which have increased incidence 
of infection (69,21,8,61,92). 
Humoral Immune System 
The humoral immune system involves B-type lymphocytes (B cells) and 
their elaboration of antibodies. IgG and IgM are the two major classes of 
antibodies whose two major functions include neutralization of organisms 
directly, and the opsonization of pathogenic organisms to facilitate 
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subsequent phagocytosis (67) . The monocyte and the PMN have surface 
receptors for complement and the Fc portion of IgG. Thus, IgM must 
"fix" complement after opsonization in order to promote phagocytosis by 
the PMN or monocyte. In contrast, IgG can promote phagocytosis by opsoni¬ 
zation directly or through complement fixation (68) 
The role of the humoral immune system is well established in viral 
illness and in diseases due to the elaboration of bacterial toxins 
(e.g., diphtheria or tetanus). In these cases, antibodies directed 
against the viral organism or the bacterial toxin are correlated with 
resistance to infection (67) . In other bacterial infections the role 
of this system is less well defined. The capsules, in encapsulated 
organisms, act to inhibit phagocytosis but their opsonization is essential 
for efficient phagocytosis. Accordingly, immunization with capsular 
antigen stimulates production of anti-capsular antibodies capable of opsoni¬ 
zation and providing immunity. These capsulated organisms, including 
pneumococci, streptococci, meningococci, and H. influenza, are very common 
pathogens in hosts with hypogammaglobulinemia (31) . 
Gram negative enteric organisms have also caused infection more 
commonly in hypogammaglobulinemic patients (i.e., those with altered 
humoral immunity) and although the exact mechanism is not presently 
understood, recent studies suggest IgG opsonization (31). 
In patients with hypogammaglobulinemia, encapsulated gram positive 
and gram negative enteric organisms are the primary pathogens because 
viruses are predominantly defended against by cellular immunity. 
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Cell Mediated Immunity 
Cell mediated immunity (CMI) requires adequate numbers of T-type 
lymphocytes (T-cells) and macrophages capable of expressing delayed hyper¬ 
sensitivity. CMI is usually measured by the extent of induration to intradermal 
skin testing with "recall" antigens such as tuberculin, mumps, and 
trichophyton antigens. These "recall" antigens are antigenic substances 
to which the patient has already been exposed in the past, and should 
now be capable of expressing delayed hypersensitivity in response to its 
reintroduction. 
The many functions of the T-cell include graft rejection, contact 
dermatitis, cooperation with B-cells for antibody synthesis to most 
antigens, suppression or regulation of other humoral or cellular immune 
responses, antitumor immunity, and defense against some infections (35). CMI 
is felt to be important in protection against infections caused by intra¬ 
cellular organisms. Intracellular residence, often within the monocyte, 
provides protection from the PMN's and humoral immune response. These 
organisms include Salmonella, Brucella, Mycobacteria, Candida, Cryptococcus, 
Aspergillus, Mucor, Toxoplasma, Pneumocystis and viruses (especially herpes 
viruses, vaccinia, and measles). Thus, impaired CMI would predispose the 
host to infection by any of the above organisms (31,46). 
Consequences of Impaired Host Defense 
Most pathogenic organisms are usually defended against by a specific 
system, or combination of systems, comprising the normal host defense. 
Infection by one of these organisms, thus implies a successful breach of 
one or more of the four systems of normal host defense. The following 
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classifications are generalizations and are not necessarily meant to 
be mutually exclusive. 
Many microorganisms are highly susceptible to being killed by PMN’s, 
and they rely heavily upon evasion of phagocytosis for their survival. 
The evasion of these extracellular pathogens is primarily due to the 
presence of surface factors which retard phagocytosis (25) . Opsonins 
are necessary to overcome the antiphagocytic surface factors, thereby 
facilitating effective phagocytosis by the PMN (67) . Since the presence 
of these microorganisms in tissues stimulates an outpouring of PMN’s, 
they are known as pyogenic microorganisms. Infections due to pneumococci, 
streptococci, S. aureus, H. influenza, meningococcus, gonococcus, enteric 
gram negative rods. Yersinia pestis, nocardia, and disseminated fungi 
are those extracellular infections in which opsonins and PMN's are 
decisive in recovery (25) . 
There is another group of infections in which antibody may be 
decisive in prevention or in recovery, through a mechanism other than 
opsonization. This group includes diseases resulting from exotoxin pro¬ 
duction such as tetanus and diphtheria, and viral illness. Antibodies 
bind to the exotoxin thereby neutralizing its toxic effects (35) . 
In viral illness, the antibody interacts with viral surface antigens 
thereby preventing viral attachment and host cell penetration. 
Another category of etiologic agents produces infections in which 
humoral and cellular immunity, distinct from the acute inflammatory 
response, collaborate in host defense. This is a heterogeneous group 




intracellular and includes the following infections: syphillis, 
cryptococcosis, mucocutaneous candidiasis, salmonellosis, and listerosis 
(25). 
The last group involves intracellular infections in which cell 
mediated immunity, CMI, is decisive in recovery, and humoral immune 
mechanisms play no protective role. The infecting organisms in 
this category include M. tuberculosis, M. leprae, Histoplasma capsula- 
tum, Coccidioides immitis, and Brucella (67). 
According to this classification, a defect in one of the four 
systems of normal host defense may predispose the host to infection 
by those organisms known to be defended against primarily by that system. 
However, theoretically, the risk of infection should be no greater in 
the other groups of microorganisms that are defended against by an intact 
host defense system (9). For example, a qualitative or quantitative 
defect in PMN's may significantly lower the defense to infection by the 
extracellular, pyogenic organisms, but it would not be anticipated 
to affect the risk of infection by agents known to be defended against 
by the humoral and cellular immune systems. 
' 
RATIONALE FOR STUDY 
Neutrophils are essential to host defense. They assist primarily 
against bacterial and fungal infections (17)N Any defects of neutrophil 
function, either qualitative or quantitative, might be expected to 
significantly alter host defense and thereby predispose the host to an 
increased risk of certain bacterial and fungal infections. 
Patients with qualitative neutrophil defects and no other obvious 
signs of host impairment, such as those with Lazy Leukocyte Syndrome (54) . 
Chediak-Higashi Syndrome (69,8,98), and Chronic Granulomatous Disease (21,49) 
have been shown to have increased incidence and severity of infection 
compared to the general population (61). 
Prior studies of patients with quantitative neutrophil defects 
have also demonstrated an increased incidence and severity of infection 
compared to the general population (4,10,100). In fact, some studies have 
even demonstrated an inverse relationship between neutrophil count and 
incidence of infection (10). These studies, however, have invariably 
involved a patient population with Underlying malignancy (especially 
leukemia), and one which has received cytotoxic drug therapy. The latter 
two conditions are known to affect all four systems of normal host 
defense, and thus these patients are at increased risk of infection for 
a number of reasons besides their neutropenia (30,36,100,85,46). 
The mucocutaneous barriers are compromised and the risk of infection 




mouth, esophagus, colon, and rectum (9); the obstructive phenomena 
of tumor mass near the ureters, bronchi, or biliary tract (9); the 
damage to integumentary barriers caused by tumor, venipunctures, or 
decubiti (75); the iatrogenic procedures of venous or urinary catheteri¬ 
zation (87); and the acquisition of new, often highly resistant pathogens 
from the hospital environment, notably Pseudomonas, S. aureus, and Asper¬ 
gillus (79). All these factors interacting, in addition to the neutropenia 
itself, place the patient at a great risk of overwhelming infection. 
The inflammatory response is also hampered by malignancy and its 
chemotherapy. Specifically, abnormal leukocyte function has been reported 
in both acute and chronic myelogenous leukemia, including decreased 
adhesiveness, phagocytosis, and microbicidal activity (57,60,70). Cortico¬ 
steroids are known to impair the neutrophilic and monocytic inflammatory 
response, presumably due to decreased adhesiveness to the vascular 
endothelium (27). Radiation therapy has been reported to cause granulocyte 
dysfunction (7,91). In addition, many chemotherapeutic agents including 
vincristine (63), vinblastine (19), and colchicine (19,48) have been 
shown to alter normal neutrophilic chemotaxis, in vitro. All these potential 
defects in neutrophil function, coupled with a reduced number of circulating 
neutrophils found in any neutropenic state, could conceivably further 
increase the patient’s risk of infection. 
A derangement in the humoral immune system, usually manifest as 
hypogammaglobulinemia, is also found in some cancer patients (68,52). 
Hypogammaglobulinemia is an accompaniment of early disease in patients 
with multiple myeloma and chronic lymphocytic leukemia (9,52), both 
diseases of the B-cell system, while the acute leukemias, chronic myelogenous 
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leukemia, and solid tumors have been reported to have normal immuno¬ 
globulin levels (35,52). Chemotherapy (41), and radiation therapy (91, 
56) may also depress antibody responses. Also, abnormalities of complement- 
mediated functions and of the third component of complement, C3, have been 
associated with increased susceptibility to infection (2). Thus a reduction 
in opsonins in an already neutropenic patient can increase the predisposition 
to infection (68,2,24,50,33), especially due to encapsulated gram positive 
cocci and enteric gram negative bacilli (25). 
Finally, cell mediated immunity can be impaired to a clinically signi¬ 
ficant degree in some malignancies (36). The prototypic malignancy asso¬ 
ciated with cellular anergy is Hodgkin’s Disease in which negative tests 
for CMI correlate with later stages of the disease (99,38). Similar obser¬ 
vations have been made for patients with non-Hodgkin’s lymphoma (38). 
In addition, corticosteroids have shown to be effective suppressors of CMI (27, 
47) . Some studies have demonstrated a relationship between depressed 
CMI and increased susceptibility to infection by intracellular bacteria, 
fungi, protozoa, and viruses (85,100) 
In summary, no published study has examined the risk of infection 
in neutropenic patients without malignancy or cytotoxic therapy. Since 
both malignancy and its therapy have been shown to predispose the host 
to infection, it is difficult to ascertain the role that neutrophil count, 
alone, plays in infection. In this study we attempted to reduce other 
factors which may impair host defense against infection, and thereby con¬ 
centrate more specifically on the risk of neutropenia only. 
. 
METHODS 
I. Case Selection 
This study was a ten year retrospective chart review involving 
all patients discharged from Yale-New Haven Hospital with the discharge 
diagnosis of aplastic anemia or neutropenia in the period from 1969-1978. 
These two filing categories included all patients with the discharge 
diagnosis of neutropenia of any cause during their hospitalization. 
The patients' charts were pulled and then examined. The selection 
of patients for this review was based on the following criteria: 
1) All patients had to have neutrophil counts of less than 1500 
for at least two days. 
2) The calculation of absolute neutrophil count was based on 
two or more consecutive CBC's (WBC count with differential) 
over a period exceeding two days. 
3) The chart had to be complete for the entire hospitalization 
including a discharge summary, daily temperature chart, 
hematology lab results, and bacteriology lab results. 
4) Patients were excluded from the study when other evidence 
of host impairment other than neutropenia was present, including 
a. disseminated malignancy; 
b. cytotoxic drug therapy; 
c. corticosteroid therapy; 
d. active systemic diseases known to impair host 



















Neutropenia was defined as an absolute 
neutrophil count of less than 1500. 
An infection was identified by the presence 
of any of the following: 
1) a recognizable focus by physical examination. 
2) positive bacterial cultures consistent with 
the clinical picture of the patient. 
3) any positive blood culture with clinically 
significant organisms. 
4) improvement in equivocal clinical findings 
temporally related to an appropriate, 
culture-based antibiotic regimen. 
5) definitive radiologic findings consistent 
with infection. 
6) positive biopsy findings. 
7) positive autopsy results. 
An infection documented by any of the above 
criteria, occurring at the time of admission 





New Episode of 
Neutropenia 




The development of the above criteria for 
infection 48 hours or more after admission 
into the hospital. 
A significant febrile episode was defined as 
an oral or rectal temperature greater than 
100°F, persisting at least 24 hours, and 
noted by the patient care staff to be clinically 
significant. Transient temperature elevations 
clearly due to the transfusion of blood products 
were not included in the study. 
A new episode of neutropenia was defined as the 
onset of neutropenia at least 48 hours after 
the apparent resolution of a prior episode. 
A new episode of infection was defined as 
the recurrence of infection after the patient 
had been afebrile and without signs of infection 
for at least 72 hours or identification of a 
new pathogen in a patient who remained febrile 
on antibiotics. 
Any neutropenic episode lasting greater than 
6 months, continuously. (The absolute neutrophil 
count may range anywhere between 0-1500/mm3. 
Any neutropenic episode resolving within 6 
months of onset. 
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Incidence of Infection - 
per 100 Hospital Days 
Incidence of Infection - 
per Hospital Admission 








The total number of new episodes of nosocomial 
infections occurring within 100 total patient 
days in the hospital. 
The total number of new episodes of nosocomial 
infection divided by the total number of 
hospital admissions. 
The total number of community acquired 
infections divided by the total number of 
hospital admissions. 
Upper respiratory infection was defined 
to include the common viral URI, pharyngitis, 
sinusitis, otitis media and croup, alone or 
in combination with one another. The diagnosis 
was based on physical exam in the majority 
of cases. 
Lower respiratory infection included pneumonia 
and bronchitis of any cause. 
A skin infection was a broad category defined 
to include wound infections, cellulitis, 
superficial abscess, bullae, and other skin 
lesions. 
Anorectal infections included anorectal 







Cell Mediated Immunity 
A urinary tract infection was defined to 
include cystitis, pyelonephritis, and bacteruria 
with greater than 10^ pathogenic microorganisms 
obtained from a clean catch specimen. 
The upper limit of normal for monocyte 
level is considered 400-600 per mm (29) . Mono¬ 
cytosis was defined as greater than 400 
monocytes per mm^. 
Immunoglobulin levels were measured by a 
radial immunodiffusion test. The age-corrected 
range of normal (in mg/100 ml) includes (53): 
IgG IgA 
Newborn 600-2000 0-30 <10 
Children (6-8 years 450-1600 20-150 50-300 
old) 
Adults (> 9 years 600-2000 20-250 60-400 
old) 
CMI was assessed by the extent of induration 
to intradermal skin testing with recall antigens, 
including tuberculin, mumps, Candida, and 
trichophyton (15). Normal CMI was defined as an 
area of induration at least 10 mm in diameter. 
Questionable CMI was defined as 5-10 mm of indura¬ 
tion, and abnormal CMI was less than 5 mm. 
— 
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Recent Antibiotic - In patients with normal renal and hepatic function. 
Treatment 
a subtherapeutic level of antibiotic was generally 
assumed to be reached by 48 hours after cessation 
of therapy. Recent antibiotic treatment was defined as 
any patient having received any antibiotic 
within 48 hours of time of infection. 
Ill. Method of Chart Review 
Each patient’s chart with the discharge diagnosis of aplastic 
anemia or neutropenia was examined for the absolute neutrophil count 
throughout their hospitalization. Patients having less than 1500 
absolute neutrophils for at least two days during the course of a hospi¬ 
talization were considered eligible for the study, providing they exhi¬ 
bited no evidence of systemic disease or drug therapy known to cause 
serious host impairment,(as outlined under Case Selection). Each 
qualifying hospitalization was then examined for the following: patient’s 
age, sex, race, diagnosis, presumed etiology, hospitalization number 
during this 10 year period, WBC count with differential, absolute numbers 
of neutrophils and lymphocytes and monocytes, duration of neutropenia 
prior to admission, duration of neutropenia after admission, febrile episodes, 
temperature, infection site, episode of infection during this hospitaliza¬ 
tion, proof of infection, infection after how many hospital days, total 
number of hospital days, organism responsible for the infection, concurrent 
disease, survival, cause of death, recent antibiotics, catheterization prior 
to infection, duration of catheterization prior to infection, diagnostic 
procedures performed before infection, number of prior episodes of 
■ 
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neutropenia, immunoglobulin level, complement level, and degree of 
anergy. 
The data were analyzed using the computerized Statistical 
Analysis System (SAS) Package (39) . All variables were cross tabulated 
using the Chi-Square Test for Association. Findings were considered 
significant if the probability (p-value) was less than or equal to 
.05, using a two tailed test (26). 

RESULTS 
I. The Study Population 
Development of the Study Population 
In the ten year period from 1969 through 1978 there were 816 
admissions with the discharge diagnosis of neutropenia or aplastic 
anemia (See Table 1). Out of 816 admissions involving neutropenic epi¬ 
sodes, only 188 admissions were eligible for the study; 23% eligibility. 
Only 145 of the 188 eligible charts were retrieved, giving a recovery 
rate of 77%. There were 157 episodes of neutropenia involving 145 admis¬ 
sions, in a total of 197 patients satisfying the criteria of the study. 
Forty nine percent of the total neutropenic episodes (399 of 816) 
involved patients with malignancy, and were therefore ineligible for 
the study. The percentage of neutropenic episodes disqualified for other 
reasons included 7% having received cytotoxic drug therapy, 4% with 
chronic alcoholism, 3% with Diabetes mellitus, 2% with rheumatoid arthritis, 
2% with SLE, and 1% with chronic renal failure and uremia. Overall, 
70% of neutropenic episodes were ineligible. 
Characteristics of the Study Population 
The 107 patients in the study were composed of 57 males (53%), 
50 females (47%), 85 whites (79%), and 22 nonwhites (21%). 
For all episodes, the median age of eligible patients was 15 years old, 




varies markedly from that of the general patient population at Yale- 
New Haven Hospital (89). 
The sex distribution included 101 males (64%) and 56 females (36%). 
The race distribution included 132 whites (84%) and 25. nonwhites (16%). 
Further defining the study population, we find that the whites are 
comprised of 68% males and 32% females while the nonwhites are 44% male 
and 56% female. Fifty seven percent of the study population is white 
male, 26% is white female, 9% is nonwhite female, and 7% is nonwhite male. 
There were 8 different diagnoses assigned to the various members 
of the study population to describe their neutropenia. The breakdown 
was as follows: 39% neutropenia, 15% aplastic anemia, 12% congenital 
neutropenia, 12% leukopenia, 10% pancytopenia, 6% granulocytopenia, 4% 
agranulocytosis, and 2% cyclic neutropenia. 
The etiology of the neutropenia was unknown in 55% of the episodes. 
Of the 45% of episodes with known etiology, 35% were secondary to a 
drug reaction, 21% were due to a congenital syndrome, 18% were presumed 
secondary to a viral illness, and the remaining 24% were due to immune 
reactions, solvent exposure, familial conditions, and hypersplenism (See 
Table 3). The viral infections presumed to be responsible for the resul¬ 
ting neutropenia were not included in the ensuing infection statistics. 
Assuming the normal range of WBC counts to be 5,000-10,000, 73% 
of the patients were leukopenic as well as neutropenic during their 
episodes, and 8% had a leukocytosis (See Table 4). 
The breakdown of the study population by neutrophil count reveals 
38% of episodes occurred in patients with less than or equal to 250 PMN's, 
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13% in patients with 251-500 PMN's, 23% in patients with 501-1000 PMN's, 
and 26% in patients with 1001-1500 PMN's (See Table 5). 
The median duration of neutropenia after hospitalization was 4 
days. Sixty two percent of the neutropenic episodes resolved within 
5 days, and 75% of the neutropenic episodes resolved within 8 days. 
Eighty three of the 107 patients, 78%, had an acute episode of neutro¬ 
penia (defined as a neutropenia that resolved within 6 months of onset). 
Chronic neutropenia (defined as a neutropenia lasting longer than 6 
months) was found in 22% (24 of 107) of patients. Further, 80% (126 of 
157) of all neutropenic episodes involved patients with acute neutropenia, 
while 20% (31 of 157) involved patients with chronic neutropenia. 
There was a significant association between the duration of neutro¬ 
penia and age (p = .012). Acute neutropenic episodes were more common 
in the first two decades of life (See Table 37). 
In general, most of the patients had an acute episode of neutropenia 
necessitating only one hospital admission. Only 19 of 107, or 18% of patients 
had more than one hospital admission for their neutropenia. In addition, 
only 5 of 107, or 5% of patients experienced more than one episode of infection 
during any one admission. 
The outcome of the neutropenia among the 107 patients was as follows: 
Of the 83 patients admitted with an acute neutropenia, 62 resolved, 17 
became permanent, and 4 died. Of the 24 patients admitted with chronic 
neutropenia, 19 continued, and 5 died. 
For the entire study population, there was a total of 2033 days spent 
hospitalized, of which 1329 days were spent with neutrophil counts of less 
than 1500 (See Table 13). 
•* 
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Eighty seven of 157, or 55% of the episodes occurred in patients 
for the first time. Thirty five percent of the episodes occurred in 
patients having had at least 3 prior neutropenic episodes. 
The total number of days hospitalized ranged from 1-180 days, 
with a median of 7 hospital days (See Table 6). 
Only 15% of the patients developed neutropenia during hospitaliza¬ 
tion, while 85% of the patients were admitted with neutropenia. 
II. Fever and Infection 
Febrile Episodes 
Eighty five of the 157 neutropenic episodes (54%) resulted in a 
febrile episode (See Table 10). The median temperature for those patients 
who became febrile was 101.8° Farenheit. 
There was a statistically significant relationship between fever 
and infection (p <.001). Overall, 72 of the 85 febrile episodes were 
associated with a documented infection. Therefore fever was predictive 
of infection in 85% of cases. Fifty five of 72, or 66% of the afebrile 
episodes were'not associated with an infection. This implies that 24% 
of afebrile episodes were still associated with infection. Thus, absence 
of fever as an indicator of absence of infection is less reliable (although 
still statistically significant) than presence of fever is of presence 
of infection. In other words, the sensitivity of fever as an indicator of 
infection was 81%, and its specificity was 81%. 
We then divided the study population into two groups based on 
absolute neutrophil count. There was a statistically significant 
association (p<.001) between neutrophil count and febrile episodes, in 
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that episodes involving <250 neutrophils are more likely to be associated 
with febrile episodes than are episodes involving 251-1500 neutrophils. 
Furthermore, the statistically significant relationship between fever and 
infection remained for both groups of <250 and 251-1500 neutrophils. Forty 
seven of 60, or 78% of neutropenic episodes with <250 neutrophils developed 
febrile episodes. Forty four of the 47 febrile episodes had documented in¬ 
fections. Six of the 13 afebrile episodes were without infection. Thus, 
for patients with—250 neutrophils, fever was predictive of infection in 
94% of cases, while absence of fever was predictive of absence of infection 
in only 46% of cases. 
Thirty eight of 97, or 39% of neutropenic episodes with 251-1500 
neutrophils developed febrile episodes. Twenty eight of the 38 febrile 
episodes had documented infections. Forty nine of the 59 afebrile episodes 
were without infection. Thus, for patients with 251-1500 neutrophils, 
fever was predictive of infection in 74% of cases, while absence of fever 
was predictive of absence of infection in 83% of cases. In other words, 
fever as an indicator of infection has a 86% sensitivity and 66% specificity 
in episodes involving <250 neutrophils, and a 74% sensitivity and 83% 
specificity in episodes involving 251-1500 neutrophils. 
Infection Sites and Organisms 
The sites of infection, broken down by organ systems reveals that 46% 
of infections involved the respiratory system, 14% involved the skin, 13% 
involved the gastrointestinal system, 13% involved septicemia without any 





cardiovascular system, 3% involved the musculoskeletal system, and 
2% involved miscellaneous sites (see Table 7). 
Looking at more specific infection sites, the five major sites 
included 30% upper respiratory infections (URI), 15% lower respiratory 
infections (LRI), 13% skin infections, 7% anorectal infections, and 6% 
urinary tract infections (UTI). The remaining 29% of infections involved 
other sites (see Table 8). 
Positive organisms were documented in 64% of the episodes of 
infection (57 of 89). The most frequent infecting organisms included, 
E. coli, Candida, Pseudomonas, S. aureus, Klebsiella, Enterococcus, and 
H. influenza, accounting for 23%, 14%, 12%, 12%,9%, 5%, and 5% respectively 
of the documented organisms (see Table 9). Conversely, 70% (40 of 57) 
of the infections with documented organisms involved a "top five" organism. 
The proof of infection was obtained in a variety of ways including 
positive wound cultures, blood cultures, physical exam, chest x-ray, 
gram stain, and specimen obtained through autopsy or biopsy. One third 
of all episodes of infection were confirmed by positive wound cultures. 
One fourth of all episodes of infection were confirmed by positive blood 
cultures, and one fourth by positive physical examination. 
For a breakdown of infecting organism by infection site, refer to 
Table 30. Interestingly, S. aureus and Candida were only responsible 
for URI's and skin infections in this study. These two etiologic agents 
were responsible for all 7 URI's with documented organisms, and 5 of the 8 
skin infections with documented organisms. 
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Examination of infection sites and organisms, when broken down 
by neutrophil count, provided some significant observations. Examining 
the organ systems involved with infection only a few significant differences 
exist between patients with 5250 and 251-1500 neutrophils (see Table 25). 
Eighty two percent of infections involving the gastrointestinal system 
and 75% of infections involving the skin occurred in patients with 
250 neutrophils. In addition, 8 of 11, or 73% of the cases of septicemia 
without documented source occurred in the 5250 group. 
In the 5 major infection sites, 75% of skin infections and 100% of 
anorectal infections occurred in patients with 5250 neutrophils. In the 
three remaining major infection sites, there was a much more even distri¬ 
bution between the <250 and the 251-1500 groups (see Table 26). 
The five major infection sites comprised 58% of all infections 
in the <250 group, 45% in the 251-500 group, 39% in the 501-1000 group, 
and 12% in the 1001-1500 group. Note the decreasing incidence of infection 
involving the five major sites as the neutrophil count increased. Overall, 
the five major infection sites comprised 58% (35 of 60) of the total 
infections in patients with <250 neutrophils, but only 29% (28 of 97) 
of the infections in the 251-1500 group. Thus, lower neutrophil counts 
were associated with an increased incidence of infection involving one 
of the five major sites (p<.001). 
In patients with <250 neutrophils, a "top five" organism was 
responsible for the majority of documented infections as follows: 
100% of Klebsiella infections (5 of 5), 86% of S. aureus infections 
(6 of 7), 71% of Pseudomonas infections (5 of 7), and 67% of E. coli 
infections (8 of 13). Only 38% of documented Candida infections occurred 
in patients with 5250 neutrophils (see Table 27). 
' 
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In the 57 infections with recoverable organisms, "top five" 
organisms were responsible for 75% of infections in the £250 group, and 
only 62% of infections in the 251-1500 group (p = .30). Overall, 53% 
of all infections in the 5250 group were due to "top five" organisms, while 
only 38% of all infections in the 251-1500 group were due to these 
agents. 
Another interesting statistic was the chance of recovering the 
infecting organism. For patients with <250 neutrophils, 71% of all 
infections had a recoverable and identifiable agent, while the remainder 
of patients with 251-1500 neutrophils had a recoverable and identifiable 
agent in 55% of the episodes of infection. Thus patients with <250 neutrophils 
had a slightly better chance of recovering their infecting organisms. 
Incidence of Infection 
Eighty nine of the 157 neutropenic episodes (57%) resulted in infection 
either prior to or after admission. These 89 infections occurred in only 
57 patients, thus only 53% of the patients in the study developed infection. 
There were twice as many community acquired infections (59) as there were 
nosocomial infections. Overall, 19% of all the neutropenic episodes 
resulted in nosocomial infections, and 38% of all episodes resulted in 
community acquired infections. 
Community Acquired Infection 
A community acquired infection was recognized at the time of admis¬ 
sion in 59 of the 145 admissions, giving an overall prevalence of 41% 
(see Table 12). In the large majority of these cases, infection was the 
cause of admission. Comparing the patient with neutrophil counts <250 
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and those with 251-1500, the respective incidence of community acquired 
infection per admission was 67% versus 27%, and this difference was 
statistically significant (p<0.005). The incidence of community acquired 
infection per admission in the 5250 group was more than double that of 
all the other neutropenic patients. 
Nosocomial Infection 
Thirty of the 145 admissions were complicated by infection during 
hospitalization, giving an overall incidence of nosocomial infection 
per admission of 21% (see Table 12). The incidence of infection per 
admission in patients with—250 was 37% (18 of 49) as compared to an 
incidence of 13% (12 of 96) in patients with 251-1500 neutrophils. The 
incidence of nosocomial infection in the <250 group was significantly higher 
than that of all the other neutropenic patients (p <.001). It is also 
interesting to note that there were twice as many community acquired 
infections as there were nosocomial infections in the total study popula¬ 
tion. 
There were 18 nosocomial infections acquired during the 536 days 
spent with neutrophil counts of <250 (see Table 13). There were 3 noso¬ 
comial infections acquired during the 130 days spent with neutrophil counts 
of 251-500, 7 nosocomial infections acquired during 409 days of 501-1000 
neutrophils, and 2 nosocomial infections acquired during 254 days of 1001- 
1500 neutrophils. The incidence of nosocomial infection per 100 hospital 
days increased steadily with decrease in neutrophil count as follows: 
group 1001-1500 had 0.8 n/100 hospital days, group 501-1000 had 1.7 n/100 
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hospital days, group 251-500 had 2.3 n/100 hospital days, and group 
<250 had 3.4 n/100 hospital days. Evaluating these results in a 
broader, more relevant sense, the incidence of nosocomial infection 
for patients with <250 neutrophils was 3.4 n/100 hospital days while 
for patients with 251-1500 neutrophils the incidence was 1.5 n/100 
hospital days. Thus, for patients with $250 neutrophils there was more 
than twice the incidence of nosocomial infection per 100 hospital days 
than there was among all other neutropenic patients. 
Ill. Risk Factors for Infection 
Neutrophil Count 
For comparison, all episodes were divided into subgroups according 
to neutrophil count as follows: <250, 251-500, 501-1000, and 1001-1500. 
There was a statistically significant association between neutrophil 
count and infection (p<0.001). The overall incidence of infection, both 
community acquired and nosocomial, increased with decreasing neutrophil 
count (see Table 11). Fifty seven percent of all infections occurred in 
episodes with <250 neutrophils, while 15% occurred in the 251-500 group, 
21% occurred in the 501-1000 group, and 7% occurred in the 1001-1500. 
group.The <250 group comprised only 38% of the population but managed to 
develop 57% of all infections while the combined group of 251-1500 com¬ 
prised 62% of the population and developed only 43% of all infections 
(p = 0.001). 
Further examination reveals that 51 of the 60 episodes with counts 
< 250 developed infection, and 38 of the 97 episodes in the combined 
group with counts of 251-1500 developed infection. Thus 85% of all 
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neutropenic patients with counts of <250 entered with, or developed in¬ 
fection, while only 39% of all neutropenic patients with counts from 
251-1500 were admitted with or developed infection, and this difference 
was also significant (p <0.001). 
Duration of Neutropenia 
There was no significant difference in the incidence of infection 
between episodes of acute and chronic neutropenia (see Table 35). Sixty 
percent (76 of 126) of acute episodes of neutropenia resulted in an 
infection while 42% (13 of 31) of chronic episodes developed infections 
(p - .064). Even after controlling for neutrophil count, there was no 
significant difference between acute and chronic neutropenias. Further 
there was no significant difference in neutrophil distribution between 
acute and chronic episodes. 
Nosocomial Duration of Neutropenia 
In general, the longer the duration of neutropenia, the greater 
.the incidence of infection. Since it is difficult to assess duration of 
neutropenia prior to admission, we cannot draw valid conclusions concerning 
community acquired infections and duration of neutropenia. In reference 
to nosocomial infections, patients with <250 and 251-500 neutrophils 
had increasing incidence of infections with increasing duration of neutro¬ 
penia (see Table 14). For those patients with 501-1000 neutrophils, 100% 
of all infections developed within the first 14 days. No additional 
infections developed after that time period. Furthermore, of the patients 
with 1001-1500 neutrophils, 100% of all infections developed within the 
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first 5 days of hospitalization. In summary, increasing duration of 
neutropenia was associated with increasing incidence of infection in 
all patients with—500 neutrophils. While for patients with 501-1500 
neutrophils, there was an increase in infection seen in association 
with increasing duration of neutropenia, up to 14 days following hospital¬ 
ization, beyond which there was no increase. 
Length of Hospitalization 
Forty percent of all patients who developed nosocmial infections, 
did so within their first 5 days of hospitalization (see Table 14). 
Sixty three percent of the above patients developed their nosocomial 
infection within 14 days. Upon dividing the population according to 
neutrophil counts, we find that only 28% of the patients with <250 
neutrophils who ultimately developed nosocomial infections, did so 
within the first 5 days of hospitalization. Interestingly, 58% of 
the patients with 251-1500 neutrophils who ultimately developed nosocomial 
infections, did so within the first 5 days. Examining the onset of 
infection within the first two weeks of hospitalization, we find that 
only 50% of the i-250 group who ultimately developed nosocomial infection, 
did so within the first 14 days, while 83% of the 251-1500 group became 
infected within that time period. Even if we only count the first noso¬ 
comial infection in the course of a hospitalization and disregard the 
subsequent infections, only 38% of patients with <250 neutrophils 
developed their infection within the first 5 days, and 69% within 14 days. 
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Onset of Neutropenia 
There was no significant difference in the incidence of infection 
between patients admitted with, or subsequently developed their neutro¬ 
penia. Fifty nine percent (78 of 133) of patients admitted with neutro¬ 
penia developed an infection, while 46% (11 of 24) of patients who subse¬ 
quently developed neutropenia also developed an infection (see Table 39). 
Age 
The younger patients in the study comprised the bulk of those who 
became infected (see Table 15). Twenty two of 89, or 25% of the total 
infections occurred in infants less than 1 year of age. Twenty three of 
89, or 26% of the total infections occurred in children between the 
ages of 1-10 years old. Fifteen of 89, or 17% of the total infections 
occurred in children between the ages of 11-20 years old. The percentage 
of all infections found in each succeeding decade was as follows: 9% 
(8 of 89) in the 21-30 year olds, 0% (0 of 89) in the 31-40 year olds, 
3% (3 of 89) in the 41-50 year olds, 7% (6 of 89) in the 51-60 year olds, 
and 13% (12 of 89) in the greater than 60 year olds. Recategorizing the 
ages into four groups including infants (less than 1 year of age), 
children (age 1-20), young adults (age 21-50),and old adults (age 51 
and older), we found that 79% of all infants in the study became infected, 
57% of children became infected, 39% of young adults became infected, 
and 53% of old adults became infected. Overall, 56% of all neutropenic 
episodes in this study resulted in infection. Thus, infants with their 




study population, and young adults with their 39% infection rate were 
at a lesser risk of infection (p = 0.029). 
Sex 
As mentioned earlier, 64% of all the neutropenic episodes were 
in males (101 of 157), yet 76% of all the infections occurred in males. 
Sixty seven percent of all the neutropenic episodes in males resulted 
in infection, while only 38% of all episodes in females resulted in 
infection. Males are therefore at increased risk for infection compared 
to females (p = .0003). There were roughly twice as many males with 
neutropenic episodes than females, and the males were twice as likely 
to get infected (see Table 16). 
Race 
Whites comprised 84% of the study population (132 of 157) and they 
accounted for 87% of the infections (77 of 89). The number of whites 
who became infected versus those who escaped infection were roughly 
equal, 58% and 42% respectively. The same was true for the nonwhites 
with 48% getting infected and 52% escaping infection. Thus, there is 
no significant difference in risk of infection between whites and non¬ 
whites . 
Catheter Use 
Catheters were defined to include IV lines, heparin locks, Foley 
catheters, Penrose drains, hyperalimentation lines, tracheotomy tubes, 
or any other invasive conduits. Standard IV lines caused no increased 
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risk of infection at any time during their hospitalization. Hyper¬ 
alimentation lines, Foley catheters, and heparin locks suggest an 
increased risk of infection, but the numbers were too small to be 
statistically significant (see Table 17). 
Immunoglobulin Level 
Immunoglobulin levels were quantitatived by radial immunodiffusion 
in only 45 of the 157 episodes of neutropenia (see Table 18). Patients 
with normal as well as increased levels of immunoglobulins (particularly 
IgG) experienced no protective effect from infection, as evidenced by their 
exactly equal breakdown between those with, versus those without infection. 
In contrast, 85% (11 of 13) of patients with decreased levels-of immuno¬ 
globulins went on to develop infection. Thus there was a significant 
association between immunoglobulin levels and rate of infection, with 
decreased levels of immunoglobulins being associated with higher rates 
of infection (p = 0.05). 
Monocyte Level 
Since the upper limit of normal for monocyte level ranges from 
400-600, we defined a monocytosis as greater than 400 monocytes. Of the 
68 episodes that did not result in infection, 51% (35) had less than 
400 monocytes and 49% (33) had greater than 400 (see Table 38). Of the 
89 episodes that resulted in infection 54% (48) had less than 400 
monocytes and 46% (41) had greater than 400. Thus a monocytosis was 






There were too few patients who had their complement levels 
documented to make any significant statement. 
Delayed Hypersensitivity 
Delayed hypersensitivity as defined by standard "recall" antigen 
skin testing was checked in too small a number of patients to make 
any significant statement. 
Etiology of Neutropenia 
The etiology of the neutropenia had no bearing on the risk of 
infection. 
Recent Antibiotics 
Thirty five of the 157 episodes occurred in patients who had 
received antibiotic therapy in the course of their hospitalization (see 
Table 34). In the patients who had not received any antibiotics, 
48% escaped infection while 52% ultimately developed infection. This 
equal probability is what is expected. However, 74% of those patients 
who received antibiotic therapy developed infection within 48 hours 
of their last dose, while only 26% of them escaped infection. Thus 
recent antibiotic therapy in the neutropenic patients was not protective 
against infection, and in fact it seemed to increase the likelihood of 
infection (p = .025). It is important to note that the recent antibiotic 
therapy was usually a single drug and not the typical broad spectrum 
therapeutic regimen for neutropenic patients consisting of ticarcillin 
. 
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(or other carbenicillin-type agent) and gentamicin (37,51,75,80). 
Ninety percent of the patients who received antibiotic therapy did so 
for therapeutic purposes. Ten percent of these patients received anti¬ 
biotic therapy for infection prophylaxis, and 100% of this smaller 
group went on to develop infections. Thus prophylactic antibiotic treat¬ 
ment of neutropenic patients seemed to further increase their incidence 
of infection. 
IV. Outcome of Neutropenia 
Chronic vs. Acute Neutropenia 
As discussed earlier, of the 83 patients admitted with an acute 
neutropenia, 62 resolved, 17 became permanent, and 4 died. Of the 24 
patients admitted with chronic neutropenia, 19 continued, and 5 died. 
Mortality 
Nine patients did not survive their episode of neutropenia 
thereby producing an overall mortality rate of 6%. 
V. Outcome of Infection 
Mortality 
The rate of infectious mortality was 9% (8 of 89). The cause of 
death was bacterial sepsis in 6 cases, fungal sepsis in 2 cases, and 
intracranial hemorrhage in 1 case. In other words, 89% of deaths in 
these neutropenic patients were due to sepsis (both fungal and bacterial), 
and specifically, 66% of deaths were due to bacterial sepsis. 
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VI. Risk Factors for Mortality 
There was a significant association between mortality and infection 
(p = .045), and mortality was greatest in patients with infection (see 
Table 20). Even when controlled for neutrophil count, we still found 
that the greatest risk factor for mortality was infection. Examining 
the mortality among those who were infected we found that 75% of mortali¬ 
ties (6 of 8) involved patients with nosocomial infections, and 25% 
involved patients with community acquired infections (see Table 39). 
Nosocomial infections comprised only 34% (30 of 89) of all infections 
but 75% (6 of 8) of all mortalities from infection. Thus nosocomial 
infections were associated with an increased risk of mortality compared 
to community acquired infections (p = .01). 
The association between neutrophil count and mortality did not 
achieve statistical significance (see Table 19). Patients with ^.250 
neutrophils comprised 38% of the neutropenic episodes (60 of 157), and 
67% of all mortality (6 of 9). Despite comprising only one-third of the 
population but two-thirds of the mortality, there was only a weak 
association between low neutrophil count and high mortality (p = .07). 
Further, when controlling for the presence of infection, neutrophil 
count was definitely not a significant risk factor for mortality. Overall, 
there was a 10% mortality rate in the <250 group (6 of 60), and only a 
3% mortality rate in the 251-1500 group (3 of 97). 
There was no significant association between duration of neutropenia 
(i.e., chronic vs. acute episodes) and mortality, although 7 of the 
9 deaths involved patients with acute neutropenia (see Table 36). 
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The onset of neutropenia (i.e., admitted with vs. developed 
neutropenia) was not significantly associated with mortality, although 
8 of the 9 deaths occurred in patients who were admitted with neutropenia. 
The five most common infecting organisms identified in this study 
were E. coli, Candida, Pseudomonas, S.aureus, and Klebsiella (see Table 
21). Seven of the 9 mortalities were due to overwhelming sepsis by one 
of these "top five" organisms including 2 by E. coli, 2 by Candida, 2 
by Pseudomonas, and 1 by Klebsiella. Seventy-seven percent of all deaths, 
and 88/o of deaths due to sepsis, were caused by a "top five" organism. 
However "top five" organisms were not associated with an increased 
risk of mortality (p = .18). 
Males comprised 64% of the study population and females comprised 
36%. In almost perfect concordance, 67% of mortalities involved males 
and 33% involved females. Thus, although males are at greater risk than 
females to become infected, they are at equal risk for mortality. 
Eight of 132, or 6% of the white patients in the study did not 
survive their episode of neutropenia. One of 25, or 4% of the nonwhite 
patients in the study did not survive. There is no significant difference 
in survival between whites and nonwhites. It is interesting to note, 
however, that 21 of the 25 nonwhites were Black and they suffered no 
mortality. 
Fifty five percent of the episodes in this study occurred in patients 
experiencing their first neutropenic episode, while 77% of the mortalities 
occurred in these patients. Upon directly comparing mortality versus 
number of prior neutropenic episodes we found that 45% of all deaths 
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(4 of 9) occurred in patients experiencing their first neutropenic 
episode, while 33% of all deaths (3 of 9) occurred in patients with 
chronic neutropenia (defined as 3 or more previous hospital admissions 
for neutropenia). Therefore, the number of prior episodes of neutro¬ 
penia is no indication of risk for mortality. 
Examining the mortality within each age group, broken down by 
neutrophil count, we found that the 1 infant death involved a patient 
with 251-1500 neutrophils, 4 of the 5 childhood deaths involved patients 
with £250 neutrophils, there were no deaths among the young adults, 
and 2 of the 3 old adult deaths involved patients with — 250 neutrophils 
(see Table 32). 
The breakdown of mortality by age group (see Table 22) reveals 1 
death in the infants (age less than 1 year), 5 deaths in the children 
(age 1-20 years), 0 deaths in young adults (age 21-50 years), and 3 
deaths in old adults (age 51 and older). The corresponding mortality 
rates for these groups are 4% in infants, 8% in children, 0% in young 
adults, and 10% in old adults. It is interesting to note that the 
greatest mortality rate for any one decade was 14.2% for children aged 
11-20. Infants comprised 18% (28 of 157) of all episodes, 25% of all 
infections, and 11% (1 of 9) of all mortality in this study. Children 
comprised 43% (67 of 157) of all episodes, 43% of all infections, and 
56% (5 of 9) of all mortality. Young adults comprised 18% (28 of 157) 
of all episodes, 12% of all infections, and 0% (0 of 9) of all mortality. 
Old adults comprised 21% (33 of 157) of all episodes, 20% of all infections, 
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and 33% (3 of 9) of all mortalitites. Although the numbers were too 
small to determine a significant association, the highest risk of 
mortality involved the old adults with their 10% mortality rate, and 
the lowest risk of mortality involved the young adults with their 0% 
mortality rate. 
Six of 9, or 67% of all mortalities occurred in patients who had 
received recent antibiotic therapy (see Table 34). Ninety eight percent 
of all those who did not receive recent antibiotic therapy (119 of 122) 
survived their neutropenic episodes, while only 83% of those who did 
receive recent antibiotic therapy (29 of 35) survived. In other words, 
there was a 17% mortality among those who received recent therapy and 
only a 2% mortality among those who did not. Thus, recent antibiotic 
therapy was not protective against mortality and in fact, it was associated 
with an increased risk of mortality (p = 0.001). Therefore recent 
antibiotic therapy was a significant risk factor for mortality. 
Eight of the 9 deaths, 89%, occurred in patients with <400 monocytes 
(see Table 38). The mortality rate was 10% (8 of 83) in patients with 
>400 monocytes, and only 1% (1 of 74) in patients with 5.400 monocytes. 
Thus, a monocytosis was associated with reduced mortality (p = 0.025). 
The numbers were too small to make any comment about a significant 
association between mortality and the following potential risk factors: 
coexistent disease, ability to mount a febrile episode, immunoglobulin 
levels, complement levels, and cell mediated immunity. 
Thirty three percent of deaths in this study occurred in patients 
with infections of one of the five major infections sites (LRI, URI, 
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skin, anorectum, and UTI), while 56% of deaths occurred in patients with 
infection of other less common sites, and 11% of deaths were not associated 
with sepsis (see Table 23). Although the five major infection sites 
comprised 71% of all infections, they only comprised 33% of all mortalities. 
The mortality rate was 5% (3 of 60) for patients with infection of one of 
the five major sites, and 17% (5 of 29) for patients with infection of 
other less common sites. Specifically, 5 of the 9 mortalities were due to 
septicemia without a documented source, and these 5 deaths comprised all 
of the infectious deaths not occurring in a major site. Therefore it 
was more correct to state that sepsis without a documented source was 
a significant risk factor for mortality compared to infection of any 
identifiable site (p = 0.001) and the rate of mortality in this group of 
patients was 42%. 
VII. Miscellaneous Factors Related to Neutropenia 
Duration of Hospitalization 
For convenience, we divided total hospital days into three cate¬ 
gories as follows: 1-7 days, 8-14 days, and >15 days. Overall, 49% 
of all the patients in the study were hospitalized for less than or 
equal to 7 days. Twenty eight percent of all the patients were hospitalized 
for greater than 2 weeks. However, 52% of the patients who were hospitalized 
for greater than 2 weeks had neutrophil counts of £250. Thus patients 
with neutrophil counts of ^250 were at greater risk of longer hospitaliza¬ 




In comparing the mean values between the sexes (see Table 28), 
males had a lower mean age (20 vs. 30 years old), higher WBC count 
(4,500 vs. 3,100 NBC’s), fewer neutrophils (517 vs. 734 PMN’s), noso¬ 
comial infection occurring at a later date (12 vs. 7 days after 
admission), equal temperatures during febrile episodes (102°F), longer 
hospital stays (22 vs. 13 days), and longer duration of neutropenia 
(20 vs. 8 days). 
Infection Sites Versus Sex 
Recall that 67% of all neutropenic episodes in males resulted in 
infection, while only 37% of neutropenic episodes in females resulted in 
infection. Eighty percent (32 of 40) of respiratory system infections, 
82% (9 of 11) of gastrointestinal system infections, and 83% (10 of 12) 
of skin infections occurred in males. Thus males were at an increased 
risk of getting infections of the above three organ systems (p = 0.0063) 
(see Table 29). 
Examining the five major sites of infection, males comprised 85% 
(11 of 13) of LRI’s, 78% (21 of 27) of URI’s, 83% (10 of 12) of skin 
infections, 100% (6 of 6) of anorectal infections, and 60% (3 of 5) 
of UTI’s. Overall, 76% of all infections occurred in males. Thus 
males seemed to be at increased risk of LRI’s and anorectal infections. 
Neutrophil Count Versus Age 
For the 89 episodes that culminated in infection, some generaliza¬ 
tions can be made knowing the neutrophil count and the patient’s age. 
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Twenty percent (18 of 89) of all infections occurred in infants with 
1250 neutrophils. Twenty percent (18 of 89) of all infections occurred 
in children with 1250 neutrophils. Seventeen percent (15 of 89) of all 
infections occurred in adults (both young and old) with 1250 neutrophils. 
Thus 57% of all infections involved patients of all ages with 250 neutro¬ 
phils. Examining the various age groups, we found that 82% (18 of 22) 
of all infants who developed infection had <250 neutrophils, 47% (18 of 
38) of all children who developed infection had 5250 neutrophils, 55% 
(6 of 11) of young adults who developed infection had <250 neutrophils, 
and 50% (9 of 18) of old adults who developed infection had <250 neutro¬ 
phils. Therefore for children, young adults, and old adults (i.e., all 
those patients 1 year old or older) the risk for developing infection 
was roughly equal whether they had <250 or 251-1500 neutrophils. However, 
for infants, neutrophil counts of <250 greatly increased their risk of 
infection (see Table 31). 

DISCUSSION 
I. Non-Neoplastic Causes of Neutropenia 
Although malignancy and cytotoxic drug therapy are very common 
causes of neutropenia in a hospital population, there are many other 
etiologies as well. Non-neoplastic causes of neutropenia include drug 
reactions, industrial solvent exposure, allergic reactions, leukotoxin 
production, anti-neutrophil antibodies, hypersplenism, vitamin defi¬ 
ciencies, sepsis, inflammation, and vasomotor changes (29). There is 
also a substantial number of idiopathic neutropenias, many of which 
are chronic and/or familial. An analysis of the risk factors for in¬ 
fection in this subpopulation of neutropenic patients has been long 
overdue. 
It was not surprising to see that 49% of the 816 admissions with 
neutropenia were due to malignancy over the ten year period from 1969 
through 1978, considering the increasing incidence of cancer in the 
general population. There were 157 episodes of neutropenia eligible 
for this study, comprising a patient population that was 64% male, 
84% white, with a median age of 15 years. This differs markedly from 
the general patient population at Yale-New Haven Hospital (89) which 
is comprised of more females than males, and having an average age 
between 50 and 60 years old. This disparity may reflect a very active 




neutropenia to occur in young white males, an increased incidence of 
malignancy in the older population, and/or the possibility of early 
deaths in the pediatric population. In addition, only 45% of the 
neutropenic episodes in our study had a known etiology, one third of 
which were presumed secondary to a drug reaction. 
II. Types of Infection 
The types of infection in this study coincided with the results of 
previous studies in neutropenic patients with underlying malignancy 
(10,84,76,35). Fifty four percent of all neutropenic patients, regardless 
of neutrophil count, ultimately developed an infection; 19% developed 
nosocomial, and 38% developed community acquired infections. The five 
major sites of infection included URI's (predominantly pharyngitis), 
LRl's (predominantly pneumonia), skin, anorectum, and urinary tract. 
The most frequent infecting organisms included E. coli, Candida, Pseudo¬ 
monas, Klebsiella, and S. aureus. 
In a recent study. Sickles et al., (84) examined the signs and 
symptoms of infection in granulocytopenic patient with less than 1,000 
neutrophils per mm . The five most common types of localized infection 
were pharyngitis, skin infection, pneumonia, anorectal infections, and 
urinary tract infections (UTl's). Schimpff, in a related study (76), 
examined the diagnosis of infection in cancer patients and found that 
the major pathogenic organisms included E. coli, Pseudomonas, Klebsiella, 
S. aureus, Candida, and the hepatitis viruses. Over 80% of all infections 
involved the following six sites: lower respiratory tract, pharynx, 
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anorectal area, skin, urinary tract, and liver. Pneumonia was the most 
frequent cause of both serious infection and infectious death. In all 
patients, iatrogenic procedures and hospital acquisition of organisms 
are major predisposing factors to infection. 
In another study by Schimpff et al., (79) the origin of infection 
in acute nonlymphocytic leukemia was examined to determine the significance 
of hospital acquisition of potential pathogens. Almost all infections in 
these patients arose from the patient’s own resident flora, but in about 
half (47%) of the microbiologically documented infections the infecting 
organisms was hospital acquired. The most common infecting organisms 
were again Pseudomonas, Klebsiella, E. coli, S. aureus, and Candida. 
The predominant sites of infection remained lung, anorecturm, skin, 
pharynx, and urinary tract. As discussed in previous sections, reduced 
numbers of circulating neutrophils will cause impairment of both the 
inflammatory and humoral immune responses, thus the rate of infection, 
sites of infection, and infecting organisms in this study are all 
consistent with the critical role of the neutrophil in host defense 
(35,29,25). 
Ill. Febrile Episodes 
There is variable opinion as to the predictive value of fever 
for infection in granulocytopenic hosts. Rabb and Hoeprich (62) in 
a study of 90 leukemic patients found infection as the cause of fever 
in 70% of cases. Over 80% of febrile episodes were due to infection 
in leukemic patients in the studies of Boggs and Frei (12), Browder et al.. 
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(14) and Frei et al., (30). The study by Rodriguez et al., (66) of 
fever in all patients with neoplasm and neutropenia admitted to M.D. 
Anderson Hospital over an 18 month period, revealed that 145 of 203 
episodes, or 71% of all fevers were ultimately attributable to infection. 
Closer examination of the Boggs and Frei study demonstrates a variability 
of the predictive value of fever depending on the type of malignancy. 
Among patients with acute leukemia, 60-70% of febrile episodes were due 
to infection, while in chronic lymphocytic leukemia it is virtually 100%, 
and only 25% in patients with lymphoma. Thus although the frequency with 
which fever is predictive of infection varies with tumor type, in 
general, roughly 70% of febrile episodes ultimately are due to infection. 
In our study the presence of a febrile episode was highly correlated 
with the presence of infection. Fifty four percent of the neutropenic episodes 
resulted in febrile episodes, and 85% of the febrile episodes had a 
documented infection. Thus fever was predictive of infection in 85% 
of cases. The breakdown of this group by neutrophil count demonstrates 
a significant difference in the predictive value of fever as a sign of 
infection in the groups with less than and greater than 250 neutrophils. 
For patients with £250, fever is predictive of infection in 94% of 
cases, while in only 74% of cases in patients with 251-1500 neutrophils 
is fever predictive of infection. Our results of an 85% predictive 
value overall, and 94% for patients with 5250 neutrophils are substantially 
higher than previous studies(66,84,76,62,12,14,30). This can be explained 
by the fact that virtually all these latter studies involved patients with 
malignancies, particularly leukemia and lymphoma, which are known to cause 
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fever in their own right, independent of infection (34). Thus many of 
these previous studies involved a small but significant number of 
patients with fever due to their malignancy, thereby decreasing the pre¬ 
dictive value of fever. This study, by eliminating patients with under- 
lying malignancy, has found fever to be very predictive of the presence 
of infection. 
IV. Incidence of Infection 
Many previous studies had indicated a relationship between granulo¬ 
cytopenia and the presence of infection, however Bodey's classic study 
in 1966 (10) was one of the first to examine the quantitative relationships 
between the degree and duration of leukopenia in patients with acute leukemia. 
He demonstrated that the presence of infection in patients with acute 
leukemia is related to the level of circulating granulocytes and lympho¬ 
cytes, and the lower the level of these leukocytes, the greater the 
likelihood that infection will be present. This increasing incidence of 
3 
infection was most marked in patients with less than 500 granulocytes/mm . 
Infection was present more often during relapse than during remission, 
at every leukocyte level, suggesting that other factors besides leukocyte 
level play a role in predisposing to infection. 
The prevalence of all types of infection decreased with increasing 
levels of these leukocytes. At less than 100 granulocytes per mm , 53% 
of the patient days were spent with identified infection. The percentage 
of time spent with identified infection then decreased sharply with 
increasing granulocyte levels, and there was no further reduction at 
granulocyte levels above 1500/mm . 
A I 
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The incidence of infectious episodes also decreased with increasing 
levels of granulocytes and lymphocytes. With severe granulocytopenia 
of^100 granulocytes per mm^, 43 episodes of infection were observed 
per 1,000 hospital days and this incidence dropped sharply with increasing 
granulocyte levels, with no further reduction occurring at levels of 
>1500/mm^. 
Furthermore the proportion of time spent with identified infections 
of all types decreased with increasing granulocyte and/or lymphocyte 
levels. Infection occurred most commonly when both granulocyte and lympho¬ 
cyte levels were reduced. In addition the incidence of infection was 
greater in the presence of granulocytopenia alone than in the presence 
of lymphopenia alone. 
In predicting risk of infection, a fall in granulocyte count carried 
a 12% risk of infection. However, if granulocytopenia was already present, 
a further fall in granulocyte level resulted in a 28% incidence of infection. 
Regardless of the magnitude of the fall, the risk is greater the lower 
O 
the final granulocyte level, especially at levels f500 granulocytes/mmJ. 
The most important factor in predicting risk of infection was the 
duration of granulocytopenia. Overall, any episode of granulocytopenia, 
regardless of its duration, had a 39% chance of resulting in infection. 
As the duration of granulocytopenia lengthened, the risk of infection 
increased. There was a 60% risk of developing infection if granulocytopenia 
persisted for 3 weeks, an<3 a 100% risk for 12 weeks duration. In severely 
granulocytopenic patients with <100/mm^, the risk increased to 100% 
by 3 weeks. 
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Schimpff, in a related study (76), examined the diagnosis of 
infection in cancer patients and concluded that the most important 
predisposing factor to infection in these patients is granulocytopenia, 
and both the frequency and severity of infection are inversely related 
to granulocyte level, especially below 500 neutrophils per mm3. 
To date, there have been no published studies of the quantitative 
relationship between circulating granulocytes and infection in neutropenic 
patients without underlying malignancy or cytotoxic therapy. Recall 
that Bodey's classic study involved leukemics, many of whom had received 
cytotoxic therapy. However a study at the Hospital of the University of 
Pennsylvania (45) examined granulocytopenia as an independent risk factor 
for infection in this subpopulation of neutropenic patients. Their unpublished 
results basically agree with Bodey's findings, with some modifications. 
Over a ten year period, they reviewed 72 admissions with granulocyte 
counts of less than 1500/mmJ and satisfying the above criteria. The 
incidence of nosocomial infection per 100 hospital days did not change 
significantly until the granulocyte count fell below 250. The incidence 
of infection at that level of granulocytopenia was 4.7 per 100 hospital 
days. Patients with granulocyte counts greater than 250/mm3 were relatively 
infection free with an incidence of infection of only 0.8 per 100 hospital 
days. Furthermore, over the course of hospitalization, the overall 
O 
prevalence of nosocomial infections was 45% in patients with <250/mm , 
and only 8% in patients with 250-1500/mm3. 
In our study the overall incidence of infection, both community 
acquired and nosocomial, increased with decreasing neutrophil count. 
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The 5250 group comprised 38% of the study population but managed to 
develop 57% of all infections. The combined group of 251-1500 comprised 
62% of the population and developed only 43% of all infections. Further¬ 
more, 85% of all neutropenic patients admitted with counts of 5250 will 
enter with, or develop infection. In contrast, only 39% of all neutro¬ 
penic patients with counts from 251-1500 will be admitted with, or 
develop infection. 
The prevalence of community acquired infections increased with 
decreasing neutrophil count. The overall prevalence of community acquired 
infections was 41% of all admissions. The incidence of community acquired 
infection per admission in the <250 group was more than double that of 
all the other neutropenic patients (67% vs. 27%). 
The overall incidence of nosocomial infection per admission was 
21%. The incidence of infection in patients with <250 was 37%, as com¬ 
pared to an incidence of 13% in patients with 251-1500 neutrophils. The 
incidence of nosocomial infection per admission in the 5250 group was 
roughly three times higher than that of all the other neutropenic patients. 
It is also interesting to note that there were twice as many community 
acquired infections as there were nosocomial infections in the total 
study population. 
The results demonstrated a significant association between the 
incidence of nosocomial infections and neutrophil count. The incidence 
of nosocomial infection per 100 hospital days increased steadily with 
decreases in neutrophil count; for patients with 5250 neutrophils, the 
. 
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the incidence was 3.4/100 hospital days while for patients with 251-1500 
neutrophils, the incidence was 1.5/100 hospital days. Thus, for patients 
with £250 neutrophils there was greater than twice the incidence of 
infection than there was among all other neutropenic patients. 
Bodey* s study in leukemic patients (10) revelaed an incidence of 
nosocomial infection of 43 per 1000 hospital days (i.e., 4.3 per 100 
hospital days in severe neutropenia, while the unpublished results from 
the Hospital of the University of Pennsylvania (45) demonstrated an 
incidence of 4.7/100 hospital days, and our study showed an incidence of 
3.4/100 hospital days. The striking similarity of these results may 
reflect the fact that neutropenia superceded all other risk factors for 
infection. These 3 studies involved three different hospitals, two 
different patient populations (leukemics and patients without malignancy) 
and three different time periods. 
There could have been many possible explanations for differences 
between these three results. First, Bodeyrs incidence was derived 
for patients with <100 neutrophils, while ours was for <250 neutrophils. 
Considering the trend in our study of increasing incidence of infection 
with decreasing neutrophil count, we assume that had we isolated the 100 
group, the incidence would have been substantially higher. Second, Bodey 
examined leukemic patients who are known to have compromised host defense 
for reasons other than just neutropenia (40,9,77,34). All four systems 
of host defense (as previously described) may be altered by leukemia 
and its cytotoxic therapy including mucocutaneous barriers, the 
inflammatory response, the humoral immune system, and the cellular 
immune system. Thus his population is at increased risk of infection 
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compared to ours, even with similar neutrophil counts. Third, Bodey's 
study was conducted from 1959-1963 and the University of Pennsylvania 
study spanned 1963-1972 while ours was from 1969-1978. The decades 
separating our studies saw a greater understanding of the risk of 
infection in neutropenic patients, and the adoption of various prophy¬ 
lactic measures to prevent infection including reverse isolation, laminar 
air flow rooms, oral non-absorbable antibiotics, better defined 
guidelines for the institution of empiric antibiotic therapy, strict 
handwashing, reduction in instrumentation, and even avoidance of fresh 
fruits and vegetables (29,77,78). These prophylactic measures might 
very well have contributed to a reduced incidence of nosocomial infection 
in our study, compared to the others, but evidently did not. 
The overall rate of nosocomial infection at Yale-New Haven Hospital 
is approximately 3.7 per 100 discharges, very close ,to the mean rate for 
the 18 university hospitals in the National Nosocomial Infections Study 
(89). Our results, recomputed to compare with Yale's rate, revealed a 
nosocomial infection rate of 20.6 per 100 discharges for the total neutro¬ 
penic study population. This broke down to a rate of 36.7 per 100 dis¬ 
charges for patients with -250 neutrophils, and only 12.5 per 100 discharges 
in patients with 251-1500 neutrophils. The incidence was higher in our 
study, and this confirmed the theory that neutropenic patients were at 
increased risk of infection compared to the general population, especially 
those with counts £250. 
In general, the percentage of infections increased with increasing 
duration of neutropenia. Of our patients who developed nosocomial 
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infections, 40% did so within the first 5 days of hospitalization, 
and 63% did so within 14 days. Upon dividing the population, 28% of 
the patients with 1250 neutrophils, developed their nosocomial infections 
within 5 days, and 50% did so within 14 days. This is below the percen¬ 
tages computer for the population as a whole. In contrast, of the patients 
with 251-1500 neutrophils, 58% developed their infection within 5 days, 
and 83% did so within 14 days. These results are very puzzling, for although 
we would expect to see an increasing percentage of patients developing 
infection as the duration of neutropenia increases, we would not expect 
to see the patients with greater numbers of neutrophils getting infected 
sooner. Evidently, there must have been other confounding variables 
exerting their influence on this analysis. 
Dale et al., (23) conducted a study examining 29 patients with various 
forms of chronic neutropenia defined as prolonged reduction of blood 
O 
neutrophil counts (for months to years) to less than 2,000 PMN's per mm 
in patients with other blood cell counts being normal, without spleno¬ 
megaly, and with no other ongoing disease process such as infection, 
inflammation, or malignancy, to which the neutropenia can be attributed. 
The results demonstrated elevated monocyte levels, elevated immunoglobulin 
levels, abundant myeloid precursors in the bone marrow but few mature 
PMN's, variable but consistently increased neutrophil counts in response 
to inducing agents (e.g., etiocholanolone, endotoxin, and hydrocortisone), 
diminished exudation of neutrophils in an acute inflammatory response 
but supernormal monocyte accumulation, normal urinary and serum levels 
of CSA, absence of antineutrophil antibodies, rare occurrence of life 
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threatening infections, no increase in frequency of infections compared 
to normal controls, and normal response to antibiotic therapy for in¬ 
fection. The only obvious abnormality in most of these patients with 
chronic neutropenia is a reduction in the ratio of mature to immature 
neutrophil precursors in the marrow, a "maturation arrest." The cause 
of the marrow defect is unknown in most cases. 
Many studies, including Kyle and Linman's evaluation of chronic 
idiopathic neutropenia (44), Joyce and Bogg's study of hereditary autosomal 
dominant neutropenia (42), Rodin’s study of infantile genetic agranulo¬ 
cytosis (65), and Cutting's review of familial benign chronic neutropenia 
(22) agree with Dale’s findings. The consequences of neutropenia, both 
infection and mortality, are less severe for patients with chronic neutro¬ 
penia than for patients with an acute neutropenia which occurs in idio- 
pathiv acute drug reactions, myelotoxic drug induced granulocytopenias, 
leukemia, and aplastic anemia. There are several reasons for this dif¬ 
ference. First, the latter series of conditions often involves multiple 
hematopoietic cell lines. Second, in many cases, mucosal and skin 
barriers are damaged by the underlying disease process. In addition, 
the monocytosis often seen in chronic neutropenia is not observed in 
these other conditions, and it is felt to exert a protective effect. 
Also, the inflammatory response as measured by the total number of cells 
responding, was much greater and closer to normal in patients with chronic 
neutropenia. Further, most patients with chronic neutropenia have some 
circulating neutrophils and a small but demonstrable marrow neutrophil 

reserve And finally, these patients usually had normal function of 
other components of their host defense system (23). 
In contrast to these previous studies of chronic neutropenia, 
we had no significant difference in the incidence of infection between 
patients with chronic and acute neutropenias. Furthermore, there was 
no significant difference in monocyte level between patients with acute 
and chronic neutropenias. One possible explanation for this discrepancy 
was that our group of "chronic" neutropenia was defined solely by the 
lack of resolution within 6 months, and thus any neutropenia of long 
duration was eligible. This included benign familial types of neutro¬ 
penia as well as long standing neutropenia of acute onset (e.g., idiopathi 
drug reactions) and this latter group has been described as having a 
greater incidence of infection compared to the former (23). Also, our 
group of chronic patients did not consistently have elevated levels of 
monocytes and this factor might be important in protecting against 
infection in any patient. 
From the preceding paragraphs, it is obvious that absolute neutrophil 
count is an independent risk factor for infection, with the risk of 
infection being increased as the neutrophil count is decreased. Likewise, 
the duration of neutropenia is an independent risk factor for infection, 
for the longer the duration of any level of neutropenia, the greater 
the risk of infection. However, we did not demonstrate any significant 




Many other risk factors were ascertained for infection in neutro¬ 
penic patients. Infants (less than 1 year of age) with their 79% 
infection rate are at a greater risk of infection than the general study 
population, and young adults (aged 21-50) are at a lesser risk of infection. 
The increased risk seen in infants may be due to abnormalities of the 
humoral immune system. Newborns are usually not capable of significant 
antibody production, and the only immunoglobulin found in significant 
concentration in neonatal serum is maternal IgG which crossed the placenta. 
Later on, as infants, they might still be at increased risk of infection 
because despite increasing quantities of IgM and IgA, the physiologic 
nadir of IgG occurs at 3-6 months (53). Therefore, without an intact 
humoral system, the infant could be at even greater risk of infection 
when neutropenic. In addition, some of the infants in the study had 
congenital syndromes (e.g., Schwackman's Syndrome) which may have affected 
other aspects of host defense besides neutrophil count (71). 
Sex was a positive risk factor in that males are at twice the risk 
of infection compared to females. There is no clear explanation for 
this phenomenon. 
Race was not a significant risk factor. Whites and nonwhites had 
roughly equal rates of infection. Although Black Africans and Yemenite 
Jews are known to have higher incidences of benign chronic neutropenias 
than the rest of the world population (29), and these neutropenias 
do not predispose the hosts to increased incidence of infection, this 
fact evidently did not come into play in our analysis. 
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Standard IV lines caused no increased risk of infection. However 
hyperalimentation lines, Foley catheters, and heparin locks suggest 
an increased risk of infection but the numbers were too small to be statis 
tically significant. These results are consistent with prior studies 
(28,73). 
Immunoglobulin level was a positive risk factor for infection in 
that decreased levels significantly increased the host's risk of infection 
This was consistent with the role that immunoglobulins play in the humoral 
and cell-mediated immune responses. 
Monocyte level, in particular a monocytosis, has been reported 
to exert a protective effect against infection (29) . Our results show 
that monocyte level is not a significant risk factor for infection, 
and monocytosis does not exert a protective effect against infection. 
Although monocytes are a phagocytic cell like the neutrophil, their 
rate of mobilization to sites of inflammation is relatively slow, and 
their phagocytic and bactericidal capacities are less than that of 
neutrophils (6). 
Recent antibiotic therapy in these neutropenic patients was not 
protective of infection, and in fact it seemed to increase the likelihood 
of infection. At first glance, one might have expected antibiotic 
therapy to prevent infection. However, the therapy usually consisted of 
a single drug, and was not the recommended broad spectrum therapeutic 
regimen for neutropenic patients of ticarcillin (or other carbenicillin- 
type agent) and gentamicin (75,35). Ninety percent of the antibiotic 
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therapy was for treatment of an existing infection. Ten percent of 
the patients receiving antibiotic therapy did so for prophylactic treat¬ 
ment, and 100%-of this group went on to develop subsequent infections. 
The increased incidence of infection in these treated patients may have 
been due to bacterial superinfection, fungal superinfection, or an 
initial choice of antibiotic to which the pathogenic organism was not 
sensitive (96). It is wise to consider the five most common infecting 
organisms in neutropenic patients when selecting an antibiotic regimen. 
In addition, there may be a bias in this result in that the patients 
who were sickest (i.e., the ones with the lowest neutrophil counts and 
greatest numbers of additional risk factors) were the ones most likely 
to get infected initially and need treatment. Despite this treatment, 
however, they remained at higher risk for subsequent infection. 
The major consequence of infection in neutropenic patients was 
mortality. The mortality rate was 6% among all neutropenic patients (9 
of 157), and 9% among infected patients (8 of 89). Eighty nine percent 
of all deaths were due to sepsis (both fungal and bacterial), and 
specifically, 66% of deaths were due to bacterial sepsis. 
Infection was the major risk factor for mortality in these neutropenic 
patients, even when controlled for neutrophil count. In addition, noso¬ 
comial infections were associated with an increased risk of mortality 
compared to community acquired infections. The latter result is not 
surprising considering the high rate of colonization of patients with 
nosocomial organisms (79), and the known virulence and antibiotic 
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resistance of these organisms compared to the normal resident flora 
of nonhospitalized patients (28). 
Age was correlated with risk of mortality. The highest mortality 
rate for any single decade was 14% in the 11-20 year old bracket. Yet 
examining our four arbitrarily defined age groups, we found the highest 
risk of mortality involved the old adults with their 10% mortality rate, 
and the lowest risk of mortality involved the young adults with 0% 
mortality. Older patients are often debilitated hosts for other reasons 
beside neutropenia (9) and this may explain their increased risk of 
mortality. There is no clearcut explanation for the relatively low risk 
of infection and low risk of mortality in young adults. 
The association between neutrophil count and mortality was not quite 
statistically significant (p = .07). After controlling for the presence 
of infection, there was still not a significant association between 
neutrophil count and mortality (p = .08). This was an interesting finding 
because patients with lower neutrophil counts were more likely to get 
infected, and infection was a significant risk factor for mortality. 
However, low neutrophil counts, by themselves, did not seem to be a 
significant risk factor for mortality. 
Recent antibiotic therapy was a significant risk factor for 
mortality. Sixty seven percent of all mortalities occurred in patients 
who had received recent therapy. The mortality rate was 17% among those 
who received recent antibiotics, and only 2% among those who did not. 
As discussed earlier, possible explanations for this increased risk of 
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infection and mortality include poor antibiotic choice, superinfections, 
resistant organisms, and the possibility of already having selected 
out a high risk subgroup of patients. 
Monocyte level was also a significant risk factor for mortality. 
Eighty nine percent of all mortalities occurred in patients with ^400 
monocytes. The mortality rate was 10% in patients with f400 monocytes, 
and only 1% in patients with a monocytosis of >400. Thus although a mono¬ 
cytosis was not protective against infection, it was protective against 
mortality. One can theorize that since monocytes are less efficient 
than neutrophils in host defense, they cannot necessarily prevent infection, 
but they can prevent infection from overwhelming the host. 
Infection site was determined to be a significant risk factor for 
mortality. The five major infection sites comprised 71% of all infections, 
but only 33% of all mortalities. Sepsis without a documented source 
comprised 13% of all infections, but 56% of all deaths. The mortality 
rate was 5% for infection of one of the five major sites, and a 
staggering 45% for septicemia without a source. Therefore septicemia 
without a documented source was a significant risk factor for mortality 
compared to infection of any identifiable site. These results concur 
with the findings of Bodey (9) that 65% of fatal infections in leukemia, 
and 53% of fatal infections in lymphoma patients are due to disseminated 
infection or sepsis. 
All other potential risk factors for mortality were not determined 
to be significant. These non-significant factors included onset of 
. 
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neutropenia (admitted with vs. developed neutropenia), duration of 
neutropenia (acute vs. chronic), age, sex, race, number of prior 
neutropenic episodes, and ability to mount a febrile response. 
In general, because the actual number of mortalities was small 
(9 patients), many of the determinations for significant associations 
could not be performed, and others might have changed, had there been 
a few more mortalities. 
. 
CONCLUSION 
The value of a retrospective study of this type is that it might 
assist in predicting who is at risk of infection, and when, in the 
neutropenic population with no other obvious source of host impairment 
bsides reduced numbers of circulating neutrophils. A better understanding 
of the risks for infection should enable one to institute more successful 
therapy aimed at a specific subgroup of this population. The most 
significant risk of infection and its attendant mortality occurred when 
neutrophil counts fell below 250, regardless of whether the neutropenia 
was of relatively acute onset or had been present for over 6 months. 
Another significant risk factor for infection, particularly when neutro¬ 
phil counts fell below 250, was increasing duration of hospitalization, 
especially beyond 14 days. This subgroup of patients might benefit most 
from measures to prevent infection. 
Infection in neutropenic patients often does not present with the 
classic signs and symptoms, so one must be alert to a few diagnostic 
clues. In accordance with previous studies (74,84) only erythema 
and local pain or tenderness were present in most infected patients 
regardless of site of infection or neutrophil count, while other physical 
findings were often absent. Radiologic imaging and microbiologic 
cultures were mainstays of our diagnostic modalities. In addition, 




presence of infection. In 85% of all our patients, and 94% of patients 
with neutrophil counts below 250, fever was predictive of infection. 
Thus, fever, erythema, and local tenderness were very reliable clues 
to the presence of infection in neutropenic patients, and might prompt a 
thorough search for the source and responsible organisms, as well 
as commencement of aggressive therapy. 
Management of infection presently includes four major modalities: 
barrier reverse isolation, antibiotics, WBC transfusions, and bone 
marrow transplantation. The use of these modalities, both prophylactically 
and therapeutically, is the subject of much current investigation. 
Readily available preventive measures include reverse isolation 
(77) , strict handwashing (90) elimination of fresh fruits and vegetables 
from the diet (83), and in some institutions, laminar air flow units 
(78) . There is good reason to believe that these measures could be 
useful in our patients. 
Prophylactic antibiotic regimens have been reported to be successful 
in leukemics. Oral non-absorbable antibiotics (0NArs) have effectively 
decreased the incidence of infection by suppressing gut flora (59). 
Since 3 of the 5 most common infecting agents in our study were gram 
negative rods, the prospect of the use of ONA's is particularly 
exciting. Trimethoprim-sulfamethoxazole has been reported to reduce 
the incidence of infection by Pneumocystis carnii (106). There were too 
little data in our study to make a highly definitive or absolute 
statement, but in the one subgroup that received prophylaxis, there was 
- 
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a 100% infection rate. The leukemic regimens might not be applicable 
and they have not been studied systematically in our patients. In 
addition, our limited data raises the question of whether antibiotic 
prophylaxis, in general, is effective. 
There is very limited data on WBC transfusions for infection prophy¬ 
laxis. In at least one study, prophylactic granulocyte transfusions 
were effective in preventing infection in bone marrow transplantation 
recipients, albeit under rigidly controlled conditions employing single 
donors (101). In another study in which random donors were used, 
no benefit to prophylaxis with leukocyte transfusions was observed (108). 
No data is available on the use of this treatment in patients with 
neutropenia due to the etiologies reported in our study either prophy- 
lactically or therapeutically, and is an area for future investigation. 
There have been several studies documenting effective therapeutic 
modalities for infection in cancer patients, many of whom were also 
granulocytopenic. Antibiotics have been the mainstay of therapy. A 
number of studies (37,51,80) have demonstrated the effectiveness of 
empiric carbenicillin and gentamicin in the treatment of presumed 
infection in granulocytopenic cancer patients. The sites of infection 
and infecting organisms are surprisingly similar in leukemics and our 
neutropenic patients. The most common sites of infection in both groups 
include upper respiratory tract, lower respiratory tract, skin, urinary 
tract, and anorectum (30, 84). The most common infecting organisms, 
in both groups include E. coli. Pseudomonas, Klebsiella, S. aureus 
and Candida (48,84). Because of these similarities, it seems reasonable 
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to consider the use of empiric carbenicillin and gentamicin therapy 
in our patients, although no definitive study has yet been done. 
Investigation of granulocyte transfusions in the therapy of infection 
in granulocytopenic patients has revealed its efficacy for certain sub¬ 
sets of the leukemic population. In neutropenic patients with documented 
septicemia, granulocyte transfusions have definitely been shown to improve 
survival (103,104,108). The contribution of granulocyte transfusions 
to survival in infections not accompanied by septicemia or infections 
with nonbacterial organisms is not clear (102). It is also recommended 
for improved survival that these patients have a reasonable expectation 
of recovering some of their bone marrow function so that the decision to 
initiate granulocyte transfusions also be based on whether the patient 
is expected to recover from his neutropenia, and whether, with recovery, 
his survival will be measurably improved (105). There were too few 
patients in our study who received WBC transfusions to be able to note 
any benefit. In addition it would be a difficult area for investigation 
due to the low frequency of occurrence and the heterogeneous etiologies 
for the neutropenia. However, there are lessons to be learned from 
the leukemics which might somehow be applicable to our population. 
The ultimate form of infection management is to attempt a "permanent" 
correction of the neutropenic state. Some studies have documented 
partial correction of neutropenia on every other day prednisone therapy 
(27). More recently, bone marrow transplantation has been investigated 




with acute leukemia, marrow transplantation from an identical twin 
donor has been associated with complete remission rates approximating 
90% (107,94,95). Some progress is being made toward resolution of the 
problems of transplantation biology, especially in better understanding 
the major histocompatibility complex (95). The subset of patients suf¬ 
fering from chronic myeloid hypoplasia due to any of the etiologies 
identified in our study, might be expected to have a favorable response 
to marrow transplantation since their marrow resembles the barren, 
hypoplastic marrow observed in the leukemic following administration of 
cytotoxic chemotherapy (prior to their transplant). This might be an 
exciting area for future investigation since our study demonstrated 
the critical role that neutrophils play in host defense, and a modality 






Figure 1. Scheme of stem cell differentiation and granulopoietic 
maturation. 
From: W.J. Williams et al., Hematology (New York: McGraw-Hill, 
1977), p. 700. 
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HUMORAL CONTROL OF GRANULOPOIESIS 
Figure 2. Tentative scheme of humoral regulation of granulo¬ 
poiesis. Arrows from the monocyte, macrophage, 
and lymphocyte undergoing blastogenesis indicate 
stimulation (positive feedback) of the committed stem 
cells via colony-stimulating activity. Arrow from 
the mature granulocyte (PMN) represents negative 
feedback or inhibition of granulopoiesis at the stem 
cell level. 
From: W.J. Williams et al., Hematology (New York: McGraw-Hill, 






Figure 3. The bone marrow compartment is usually divided into 
the mitotic, or proliferating compartment and the 
maturation and storage compartment. The mitotic 
compartment consists of granulocytes through the 
myelocyte stage of development; the maturation and 
storage compartment consists of metamyelocytes and 
mature PMN neutrophils. 
Cline, The White Cell, Harvard University Press, 
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Pool Egress ^ 
(Pseudoneutropenia) 
Figure 4. The types of neutropenia refer to those described in 
Figure 5. The size of each granulocyte pool [stem 
cell, mitotic (Mi), maturation and storage pool (MSP), 
marginal granulocyte pool (MGP) and circulating granu¬ 
locyte pool (CGP)]is schematically represented by the 
size of each cross-hatched area. The rate of cell 
flow into and out of each compartment is proportional 
to the size of the arrow. 
From: W.J. Williams, et al.. Hematology (New York: McGraw-Hill 
1977) p. 719. 
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Type I Reduced granulocytopoiesis 
Characterized by marrow myeloid hypoplasia. There is reduction in both total and effective granulocyto- 
Type la 
poiesis 
Predictable (chemotherapy) drug-induced granulocytopenia 
Reactions are slow in onset and are dose-dependent. Damage to stem cells and proliferating myeloid cells is 
incurred through a variety of mechanisms (alkylating agents, antibiotics, etc.). 
Type lb Idiosyncratic (chemotherapy) drug-induced granulocytopenia 
Reactions are slow in onset and dose-dependent, but there is wide variation in individual susceptibility 
(e.g., phenothiazide derivatives). 
Type Ic Idiosyncratic (hypersensitivity) drug-induced granulocytopenias 
Reactions are of variable time in onset and usually are dose-independent. The mechanism of granulocyto¬ 
poiesis interruption is unknown. Reactions may be acute, lasting from days to weeks or chronic, lasting from 
months to years. 
Type II Increased ineffective granulocytopoiesis 
Increased intramedullary destruction of granulocytes results in increased total but diminished effective 
granulocytopoiesis. The marrow is characterized by myeloid hyperplasia. 
Type IIa Predictable (ineffective) drug-induced granulocytopenia ' — 
Reactions are slow in onset and are dose-dependent, with wide individual susceptibility. Frequently the 
marrow is megaloblastic due to folic acid deficiency (e.g., methotrexate, diphenylhydantoin). 
Type III Reduced granulocyte survival 
Granulocytopenia is due to increased granulocyte destruction or utilization (e.g., sepsis, hypersplenism, 
antibody). 
Type Ilia Idiosyncratic (drug-hapten-antibody) granulocytopenia 
Reactions usually are extremely rapid in onset and are dose-independent in sensitized persons (e.g., 
aminopyrine). 
Type IV Combination (Type I or 11 and Type III) granulocytopenia 
Diminished effective granulocytopoiesis combined with increased peripheral destruction or utilization may 
result in severe neutropenia (e.g., sepsis, antibody). 
Type IVa Drug-induced (combination) granulocytopenia 
Drug-activated antibody may accelerate peripheral granulocyte survival and eventually cause marrow myeloid 
damage (e.g., aminopyrine). 
Type V Pseudoneutropenia 
Total granulocyte pool is of normal size, but apparent granulocytopenia is due to shift of granulocytes from 
the circulating to the marginal pool. 
Type Va Drug-induced pseudoneutropenia 
Reactions usually are secondary to vasomotor changes (e.g., histamine). 
*Note that a small letter following a Roman numeral designates the subgroup class of drug-induced granulocytopenia. 
Figure 5. Functional classification of granulocytopenic disorders.* 
From: W.J. Williams, et al., Hematology (New York: McGraw-Hill 
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Hydroxychloroquine (Plaquenil) Ib 
Plasmochin — 
Quinine — 
Pyrimethamine (Daraprim) Ha 
ANTITHYROID 
Carbimazole Ib, Ic 
Methimazole (Tapazole) Ib 
Methyl thiouracil (Methiacil) Ib, Ilia 
Propyl thiouracil Ib, Ic, Ilia 
Thiouracil Ib 
CARDIOVASCULAR AGENTS 
Dioxide Ib, Ic 
Procainamide (Pronestyl) Ib, Ic 
Quinidine Ic 
Methyl dopa (Aldomet) Ic 
Propanalol Ic, Ilia 
DIURETICS 
Acetazolamide (Diamox) Ic 
Chlorthalidone (Hygroton) Ic 
Chlorthiazide (Diuril) Ic 
Ethacrynic add Ic 
Hydrochlorthiazide (Hydrodiuril) Ic 
Mercurials (Mercuhydrin, etc.) Ic, Ilia 
HYPOGLYCEMIC AGENTS 
Chloropropamide (Diabinese) Ic, Ilia 
Tolbutamide (Orinase) — 
PHENOTHIAZINES 
Chlorpromazine (Thorazine) lb. Ilia 
Mepazine (Pacatol, Pecazine) lb 
Methotrimeprazine lb 
Methylpromazine lb 
Prochlorperazine (Compazine) lb 
Promazine (Sparine) lb 
Thoridizine (Mellaril) lb 
Triflupromazine (Mepazine) lb 
Trimepazine lb 
SEDATIVES AND NEUROPHARMACOLOGIC AGENTS 
Chlordiazepoxide (Librium) — 
Desimipramine — 
Diazepan (Valium) — 
Imipramine lb 
Levo Dopa lb 
Meprobamate (Miltown, Equanil) — 
SULFONAMIDE ANTIBIOTICS 




Sulfadimethoxide (Madribon) Ic, IHa 
Sulfaguanidine Ic 
Sulfamethoxydiazine Ic 
Sulfamethoxypyridazine (Kynex) Ic, Ilia 
Sulfanilamide lb, Ic 
Sulfapyridine (Dapsone) Ic, Ilia 
Sulfasalazine ib, (c - 
Sulfisoxazole (Gantrisin) lb, Ic 
Sulfathiazole ib ic 
MISCELLANEOUS 
Allopurinol (Zyloprim) Hc 
Benzene ]a jc 
DDT (Chlorophenothane) _ 
Dinitrophenol ib, Ic 
Ethanol ia, na 
Nitrous oxide ja 
Penicillamine ib, Ic 
Phenindione (Hedulin). Ic 
Dextran Va 
Histamine ya 
Iron oxide Va 
Ib, Ic, 
Ilia 
Figure 6. Classification of common (idiosyncratic) drug-induced granulocytopenias 








No. of potential discharges with diagnosis of: 
aplastic anemia 373 
neutropenia 443 
816 
Total No. of discharges with neutropenia 
No. of discharges disqualified for: 
malignancy 399 
cytotoxic drugs 60 
SLE 13 
diabetes mellitus 20 
rheumatoid arthritis 18 




Total No. of ineligible discharges 
Total No. of eligible discharges 
minus No. of lost charts 
Total No. of discharges 
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Etiology of the Neutropenia 
unknown 








% of % of Known 
Frequency Total Etiologies 
86 55 « 
25 16 35 
15 10 21 
13 8 18 
6 4 8 
5 3 7 
3 2 4 
3 2 4 
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Infection of Various Systems 
% of % of Those 
System Involved Frequency Total Infected 
no infection 68 43 X 
respiratory (resp.) 40 25 46 
skin 12 8 14 
gastrointestinal (GI) 11 7 13 
septicemia without source 11 7 13 
genitourinary (GU) 7 4 8 
cardiovascular (CVS) 3 2 3 
musculoskeletal (MS) 3 2 3 
miscellaneous 2 1 2 

Table 8 
Infection of Various Sites 
% of Those 
Site Frequency Infected 
lower respiratory tract (LRI) 13 15 
upper respiratory tract (tJRX) 27 30 
skin 12 13 
anorectum 6 7 
urinary tract (UTI) 5 6 
others 26 29 

Table 9 
Breakdown of Infecting Organisms 
in Patients With Infection 
Organism Frequency 
% of Those With 
Documented Organism 
no organism 32 
E. coli 13 
Candida 8 
Pseudomonas 7 
S. aureus 7 
Klebsiella 5 
Enterococcus 3 
















Is fever predictive of infection? 
FEVER 
NO YES 
no infection 55 13 
positive infection 17 72 
Broken down by neutrophil count 
£250: FEVER 
NO YES 
no infection 6 3 
positive infection 7 44 





















No. of Episodes 
Episodes as 
Percent of Total 
<250 9 51 60 85% 
251-500 7 13 20 65% 
500-1000 17 19 36 53% 























































cn rH W 
a cd d 
o •H O 
o •H s -h 
cn rd O H 
• cn 4-> CJ O CO CO CNJ 
o •H •H O 0) f—1 
a 6 Us cn Mm 
X) o d 




4-J cn •h cn 
a e d xi d 
QJ o d oi o 
•H g 5m -h S'? S'? 6^ &-S 
d MM cn g -H 4-1 r>. CO CO o 
M o cn o d u UO CO i—1 
•H cj cr cu 
4m S'? S O mm 
O X x c d 







> cn •H cn 
a) d d xi d 
5m MM o d D o 
Pm O •H g U -H 
cn 6 *H 4J 
• cn o d o CO O 04 
o •H a cr1 o) co 1-1 t“H 
!Z e a mm 









• cn CTr CTN vO rH 




0) O o o 
4-J O o o 
UO o uo 
o rH 1-1 
O 4J o 1 i 1 
x d LO 
d d CN* «-1 i—1 1-1 




















































•H 03 CO 
a) £ a n 
cj o 
d u CO «H 
03 o d CO CO CX3 
03 CO o 4-4 • • • • 
•H o •H •H CO CM rH o 
O s 4-1 a 
d O CO 
M 4-4 03 o 







o o 4-1 
a cj 00 co CM 
• o 0) rH 
o CO 4-4 
IS o d 
s M 
ro CO 
4-4 4-> T3 d 
o •H 0) o 
d 3-4 •H 
• 3 •H 4-J CO O CM 
o £ 3 CJ co rH rH 
s § cr 03 
o CJ 4-4 





1—1 O QJ 
03 34 M3 o o^ 
•U CO o CO CO O m 
o s 3-4 in 1—1 CM 






03 4-1 CO CO m in o 
4-1 •H rO CM CM m CO 
O a cO 00 CO <3- <r 







• CO o o 43 rH 







CO 40 i—1 





>> O o 
o 4-4 o o o 
o d o o m 
rH 3 o m tH i—i 
3 O m i 1 i 
d O CM rH rH rH 
CO m o o 






































































The Occurrence of Infection During Hospitalization 
Neutrophil count 
(per rnm^) 
Infection After "n" Hospital Days 
0-5 6-14 15-21 >22 
f 250 5 4 0 9 
251-500 1 0 0 2 
501-1000 4 3 0 0 1 




Incidence of Infection Related to Age 
Age (in years) 
<1 1-10 11-20 21-30 31-40 41-50 51-60 >60 
no infection 6 16 13 7 7 3 7 9 
positive infection 22 23 15 8 0 3 6 12 











P = .0003 
% with infection 

Table 17 















44 21 0 1 0 0 1 
68 12 5 0 2 2 0 
61 36 100 0 100 100 0 % infected 

Table 18 103 






Infection % Infected 
decreased 2 11 85% 
normal 11 10 48% 
increased 6 5 45% 




Comparison of Survival by Neutrophil Count 
Survival % 
Neutrophils: NO YES Mortality 
1250 6 54 10% 
251-1500 3 94 3% 








DIED SURVIVED Mortality 
1 67 1.5% 
8 81 9.0% 




Organisms Responsible for Mortality 
ORGANISM 
Pseudo- 
E. coli Candida monas S. aureus Klebsiella Others 
No 
Survival 
2 2 2 0 1 1 
Yes 11 6 5 7 4 16 
% mortality 15.3 25 28.5 0 20 6.2 





Breakdown of Survival by Age 
AGE (in years) 




1 1 4 0 0 0 1 2 
27 38 24 15 7 6 12 19 




Breakdown of Survival by Infection Site 
Septicemia 
LRI URI Skin Anorectum UTI Without a Source Others 
NO 1 0 1 1 0 5 1 
Survival 
YES 12 27 11 5 5 7 81 
% mortality 7.6 0 8.3 
— 
16.6 0 41.6 1.2 

Table 24 
Breakdown of Total Hospital Days by Neutrophil Count 
Total Hospital Days 
Neutrophils: 1-7 8-14 >15 
<250 25 12 23 
251-500 9 8 3 
501-1000 22 4 10 




Breakdown of Infected Systems by Neutrophil Count 
SYSTEM 
No 
Neutrophils: Infection Resp. CVS GI GU Skin MS Sepsis Miscellaneous 
5250 9 20 1 9 2 9 1 8 1 
251-500 7 5 2 0 1 2 0 3 0 
501-1000 17 11 0 2 3 1 1 0 1 
1001-1500 35 
-_ 
4 0 0 1 0 1 0 0 

Table 26 






LRI URI Skin Anorectum UTI 
6 12 9 6 2 
2 5 2 0 0 
2 9 1 0 2 




Frequency of Infecting Organism Broken Down by Neutrophil Count 
Pseudo- 
Neutrophils: E. coli Candida monas S. aureus Klebsiella Others 
5250 8 3 5 6 5 9 
251-500 0 2 2 0 0 4 
501-1000 4 2 0 0 0 3 




Mean Values for Each Sex 
MALE FEMALE 
age 20 30 
WBC count 4,500 3,100 
PMN count 517 734 
infection after "n" 
hospital days 
12 7 
temperature (when febrile) 102.0 102.4 
total hospital days 22 13 




Breakdown of Infected System by Sex 
No 
Site Resp. CVS GI GU Skin MS Sepsis Miscellaneous 
Male 33 32 3 9 3 10 3 6 2 




Breakdown of Infecting Organism by Infection Site 
Infection Site 
Organism: LRI URI Skin Anorectum UTI 
E. coli 2 0 2 2 3 
Candida 0 2 3 0 0 
Pseudomonas 0 5 2 0 0 
S. aureus 1 0 0 1 0 




For Patients with a Documented Infection, 
the Breakdown of Age by Neutrophil Count 
AGE (in years) 
Neutrophils: <1 1-10 11-20 21-30 31-40 41-50 51-60 >60 
<250 18 9 9 3 0 3 3 6 
251-500 1 9 0 1 0 0 2 0 
501-1000 2 5 4 4 0 0 0 4 
1001-1500 1 0 2 0 0 0 1 2 

Table 32 
For Those Who Did Not Survive, the Breakdown of Neutrophil Count by Age 
AGE (in years) 
Neutrophils: < 1 1-10 11-20 21-30 31-40 41-50 51-60 >60 
< 250 0 1 3 0 0 0 1 1 
251-500 1 0 0 0 0 0 0 0 
501-1000 0 0 0 0 0 0 0 1 
1001-1500 0 0 1 0 0 0 0 0 

Table 33 118 
Nature of Defects of Leukocyte Function 
Function Defect Clinical Condition 
1. Delivery 




Inumber of mature cells 




















































R.K. Root and M.G. Farquhar: "Defects of PMN leukocyte function." (Clinical 




Risks of Recent Antibiotic Therapy 













p = .025 
Survived 
YES 




Incidence of Infection Broken Down by 
Duration of Neutropenia 





Neutropenia Acute 50 76 
Chronic 18 13 
For Patients with 250 neutrophils/mm^: 
Positive 
No Infection Infection 
Duration of 
Neutropenia Acute 6 45 
Chronic 3 6 
For Patients with 251-1500 neutrophils/mm 3. 
p = .064 




No Infection Infection 
44 31 
15 7 





Survival Broken Down by Duration of Neutropenia 
For all patients: 
Duration of Survival 
Neutropenia No Yes 
Acute 7 119 
Chronic 2 29 
For patients with £250 neutrophils/mm^ 
Duration of Survival 
Neutropenia No Yes 
Acute 6 45 
Chronic 0 9 











Duration of Neutropenia Broken Down by Age 
Duration of AGE ( IN YEARS) 
Neutropenia 
<1 1-10 11-20 21-30 31-40 41-50 51-60 >60 
Acute 28 26 23 14 4 6 10 15 
Chronic 0 13 1 1 3 0 3 6 









f 400_ >400 
23 27 
40 36 
p = .55 







p = .025 

Table 39 
Risk of Mortality vs. Type of Infection 
Type of Infection: Survival 
NO YES 
Community acquired 2 57 
nosocomial 6 24 
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